## Supplementary materials 5: Tables of results for evidence from randomised controlled trials

Table 1. Data for clinical outcomes for each study trialling an ERP intervention to improve recovery following colorectal surgery. Reported values are presented (mean and standard Table 2. Data for patient-reported outcomes for each study trialling an ERP intervention to improve recovery following colorectal surgery. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.10 Table 3. Data for clinical outcomes for each study trialling a Prehabilitation intervention to improve recovery following colorectal surgery. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.17 Table 4. Data for patient-reported outcomes for each study trialling a Prehabilitation intervention to improve recovery following colorectal surgery. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where Table 5. Data for clinical outcomes for each study trialling an ERP intervention to improve recovery following lower limb arthroplasty. Reported values are presented (mean and standard Table 6. Data for patient-reported outcomes for each study trialling an ERP intervention to improve recovery following lower limb arthroplasty. Reported values are presented (mean and Table 7. Data for clinical outcomes for each study trialling a Prehabilitation intervention to improve recovery following lower limb arthroplasty. Reported values are presented (mean and Table 8. Data for patient-reported outcomes for each study trialling a Prehabilitation intervention to improve recovery from lower limb arthroplasty. Mean and standard deviation Table 9. Data for all outcomes for studies trialling Rehabilitation interventions to improve recovery from lower limb arthroplasty. Reported values are presented (mean and standard Table 10. Data for all outcomes for the one study trialling a Staff Mix intervention to improve recovery from lower limb arthroplasty. Reported values are presented (mean and standard Table 11. Data for clinical outcomes for each study trialling a Prehabilitation intervention to improve recovery after cardiac surgery. Reported values are presented (mean and standard Table 12. Data for patient-reported outcomes for each study trialling an ERP intervention to improve recovery from cardiac surgery. Mean and standard deviation are presented Table 13. Data for clinical outcomes for studies trialling Specialist Ward or Rehabilitation interventions to improve recovery from cardiac surgery. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where  Table 14. Data for clinical outcomes for each study trialling an ERP intervention to improve recovery from upper abdominal surgery. Reported values are presented (mean and standard Table 15. Data for patient-reported outcomes for each study trialling an ERP intervention to improve recovery from upper abdominal surgery. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.40 Table 16. Data for all effectiveness outcomes for the one study trialling a Prehabilitation intervention to improve recovery after upper abdominal surgery. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where Table 17. Data for clinical outcomes for each study trialling an ERP intervention to improve recovery from pelvic surgery. Reported values are presented (mean and standard deviation Table 18. Data for patient-reported outcomes for each study trialling an ERP intervention to improve recovery from pelvic surgery. Reported values are presented (mean and standard Table 19. Data for all outcomes for studies trialling interventions to improve recovery from vascular surgery. Reported values are presented (mean and standard deviation (SD) unless Table 20. Data for all outcomes for studies trialling interventions to improve recovery from thoracic surgery. Reported values are presented (mean and standard deviation (SD) unless Table 21. Data for all outcomes from the study trialling an intervention to improve recovery for patients undergoing various tumour removal surgeries. Reported values are presented (mean 

		Intervention (		Com	parator		Intervention	Comparator				
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean change (95% CI)	р
Anderson 2003 <sup>1</sup>	LOS (days)	14	4.0	1.77	10	7.0	2.07			-1.60 (-2.54 to66)	-3.0 (-4.66 to -1.40)	<.001
Anderson 2003 <sup>1</sup>	Readmissions (n)	14	0		11	0						
Anderson 2003 <sup>1</sup>	Mortality (n)	14	0		11	1						.25
Anderson 2003 <sup>1</sup>	Patients with postop complications (n)	14	4		11	5				OR: 0.48 (0.09 to 2.52)		.38
Chen 2017 <sup>2</sup> (Right hemi- colectomy)	Delirium incidence (%)	32	3.1		32	6.3				OR: 0.48 (0.04 to 5.55)		.55
Chen 2017 <sup>2</sup> (Right hemi- colectomy)	LOS (days)	32	12 (median)	10 to 14 (IQR)	32	13 (median)	11.25 to 15.25 (IQR)	12.0 (3.1)	13.0 (4.3)	32 (82 to .17)	-1.0 (-2.52 to .52)	.29
Chen 2017 <sup>2</sup> (Left hemi- colectomy, LAR or AR)	Delirium incidence (%)	67	9.0		67	14.9				OR: 0.56 (0.19 to 1.65)		.29
Chen 2017 <sup>2</sup> (Left hemi- colectomy, LAR or AR)	LOS (days)	67	12 (median)	10 to14 (IQR)	67	12 (median)	10.5 to 14.5 (IQR)	12.0 (3.0)	12.0 (3.8)	0.0 (34 to .34)	0.0 (-1.16 to 1.16)	1.0
Forsmo 2016 <sup>3</sup>	Total stay, including readmissions (days)	154	5 (median)	2 to 50 (range)	153	8 (median)	2 to 48 (range)					
Forsmo 2016 <sup>3</sup>	Postop LOS (days)	154	5 (median)	2 to 50 (range)	153	7 (median)	2 to 48 (range)					

Table 1. Data for clinical outcomes for each study trialling an ERP intervention to improve recovery following colorectal surgery. Reported	1 values
are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.	

		Intervention C n Estimate Variance m		Com	parator		Intervention	Comparator				
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean change (95% CI)	р
Forsmo	Readmissions <30	154	18.8		153	13.4		_		OR: 1.46		.23
Forsmo 2016 <sup>3</sup>	Morbidity <30 days (%)	154	42.2		153	44.4				OR: 0.91 (0.58 to 1.43)		.69
Forsmo 2016 <sup>3</sup>	Mortality <30 days (%)	154	1.9		153	0						.08
Forsmo 2016 <sup>3</sup>	Reoperations (%)	154	11.0		153	7.2				OR: 1.6 (0.72 to 3.54)		.24
Forsmo 2016 <sup>3</sup>	Patients with major complication (%)	154	11.1		153	7.8				OR: 1.46 (0.67 to 3.17)		.34
Forsmo 2016 <sup>3</sup>	Patients with minor complication (%)	154	34.4		153	41.2				OR: 0.75 (0.47 to 1.19)		.22
Garcia- Botello 2011 <sup>4</sup>	LOS (days)	61	4.2	2.2	58	9.2	7.0			99 (-1.37 to61)	-5.1 (-6.94 to -3.22)	<.001
Garcia- Botello 2011 <sup>4</sup>	Readmission <30 days (%)	61	4.9		58	3.4				OR: 1.45 (0.23 to 9)		.69
Garcia- Botello 2011 <sup>4</sup>	Postoperative ileus (%)	61	19.6		58	19.0				OR: 1.05 (0.42 to 2.6)		.92
Garcia- Botello 2011 <sup>4</sup>	Vomiting (%)	61	19.6		58	17.2				OR: 1.18 (0.46 to 2.98)		.73
Garcia- Botello 2011 <sup>4</sup>	Re-insertion of nasogastric tube (%)	61	11.5		58	15.5				OR: 0.71 (0.24 to 2.04)		.52
Garcia- Botello 2011 <sup>4</sup>	Total complications (n)	61	31		58	30				OR: 0.96 (0.47 to 1.98)		.92
Gatt 2005 <sup>5</sup>	LOS (days)	19	5	4 to 9	20	7.5	6 to 10					

		Intervention n Estimate Variance		Com	parator		Intervention	Comparator				
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean change (95% CI)	р
			(median)	(range)		(median)	(range)					
Gatt 2005 <sup>5</sup>	Readmissions <30 days (%)	19	5.2		20	20.0				OR: 0.22 (0.02 to 2.2)		.17
Gatt 2005 <sup>5</sup>	GP assessments <30 days (%)	19	5.2		20	0						.30
Gatt 2005 <sup>5</sup>	Patients with complications (%)	19	47.4		20	75.0				OR: 0.3 (0.08 to 1.16)		.08
Gatt 2005 <sup>5</sup>	Mortality (%)	19	5.2		20	0						.30
Khoo 2007 <sup>6</sup>	Postop LOS (days)	35	5 (median)	3 to 37 (range)	35	7 (median)	4 to 63 (range)					
Khoo 2007 <sup>6</sup>	Postop stay including readmissions (days)	35	5 (median)	3 to 37 (range)	35	7 (median)	4 to 63 (range)					
Khoo 2007 <sup>6</sup>	GP advice sought: outcome = advice only (n)	35	4		35	7				OR: 0.48 (0.13 to 1.82)		.27
Khoo 2007 <sup>6</sup>	GP advice sought: outcome = prescription given (n)	35	4		35	3				OR: 1.29 (0.27 to 6.26)		.75
Khoo 2007 <sup>6</sup>	GP advice sought: outcome = readmitted (n)	35	3		35	3				OR: 1.0 (0.19 to 5.33)		1.0
Khoo 2007 <sup>6</sup>	Patient called ward for advice (n)	35	4		35	4				OR: 1.0 (0.23 to 4.36)		1.0
Khoo 2007 <sup>6</sup>	Mortality (n)	35	0		35	2						.15
Khoo 2007 <sup>6</sup>	Total number of complications (n)	35	9		35	18				OR: 0.33 (0.12 to 0.89)		<.05
Lee 2011 <sup>7</sup>	Postop LOS (days)	45	7 (median)	6 to 8 (range)	54	8 (median)	7 to 9 (range)					
Lee 2011 <sup>7</sup>	Total LOS (days)	45	9	8 to 10	54	10	9 to 11					

		Intervention ( n Estimate Variance r		Com	parator		Intervention	Comparator				
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean change (95% CI)	р
			(median)	(range)		(median)	(range)					
Lee 2011 <sup>7</sup>	Total complications (n)	45	6		54	14				OR: 0.44 (0.15 to 1.26)		.12
Lidder 2013 <sup>8</sup>	Actual postop discharge day (days)	27	7 (median)	5 to 10 (IQR)	30	8.5 (median)	6 to 13.3 (IQR)	7.3 (3.9)	9.3 (5.7)	39 (92 to .13)	-1.93 (-4.55 to .69)	.13
Lidder 2013 <sup>8</sup>	Total number of complications by POD5 (n)	27	15		30	20				OR: 0.63 (0.21 to 1.83)		.39
Lidder 2013 <sup>8</sup>	Patients with complications by POD5 (n)	27	10		30	13				OR: 0.77 (0.27 to 2.23)		.63
Lidder 2013 <sup>8</sup>	Total number of complications by day 30 (n)	27	15		30	27				OR: 0.14 (0.03 to 0.57)		<.01
Lidder 2013 <sup>8</sup>	Patients with complications by day 30 (n)	27	10		30	15				OR: 0.59 (0.2 to 1.7)		.33
Maggiori 2017 <sup>9</sup>	LOS (days)	130	10.6	5.3	133	10.9	5.2			06 (30 to .18)	3 (-1.57 to .97)	.64
Maggiori 2017 <sup>9</sup>	Theoretical LOS (days)	130	9.6	5.1	133	9.7	3.3			02 (27 to .22)	1 (-1.14 to .94)	.85
Maggiori 2017 <sup>9</sup>	Mortality <30 days (%)	130	0		133	0						
Maggiori 2017 <sup>9</sup>	Patients with >1 complications (%)	130	35.4		133	28.6				OR: 1.37 (0.81 to 2.3)		.24
Maggiori 2017 <sup>9</sup>	Patients with severe morbidity (%)	130	7.5		133	11.5				OR: 0.62 (0.27 to 1.45)		.27
Mari 2014 <sup>10</sup>	Day of discharge	25	4.7	2.4	25	7.7	2.4			-1.22 (-1.83 to62)	-2.95 (-4.31 to -1.59)	<.001
Mari 2014 <sup>10</sup>	Readmissions (%)	25	0		25	0						
Mari 2014 <sup>10</sup>	Complications (n)	25	1		25	0						.31

		Interv	vention		Com	parator		Intervention	Comparator			
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean change (95% CI)	р
Mari 2016 <sup>11</sup>	Day of discharge	40	4.7	1.2	43	6	1.6		<i></i>	91 (-1.37 to46)	-1.3 (-1.92 to68)	<.001
Mari 2016 <sup>11</sup>	Complications (n)	40	4		43	3				OR: 1.48 (0.31 to 7.07)		.62
Muller 2009 <sup>12</sup>	LOS (days)	76	5 (median)	2 to 30 (range)	75	9 (median)	6 to 30 (range)					
Muller 2009 <sup>12</sup>	Readmissions (n)	76	3		75	2				OR: 1.5 (0.24 to 9.24)		.66
Muller 2009 <sup>12</sup>	General complications (n)	76	7		75	21				OR: 0.26 (0.1 to 0.66)		<.01
Muller 2009 <sup>12</sup>	Surgical complications (n)	76	9		75	16				OR: 0.5 (0.2 to 1.2)		.12
Muller 2009 <sup>12</sup>	Patients with a complication (n)	76	13		75	28				OR: 0.35 (0.16 to 0.74)		<.01
Pappalardo 2016 <sup>13</sup>	Dischargable day: POD 4	25	17		25	0						
Pappalardo 2016 <sup>13</sup>	Dischargable day: POD 5	25	5		25	5						
Pappalardo 2016 <sup>13</sup>	Dischargable day: POD 6	25	3		25	8						
Pappalardo 2016 <sup>13</sup>	Dischargable day: POD 7 or more	25	0		25	7						
Pappalardo 2016 <sup>13</sup>	Mortality <30 days (%)	25	0		25	0						
Pappalardo 2016 <sup>13</sup>	Anastomic leakage (n)	25	3		25	2				OR: 1.57 (0.24 to 10.3)		.64
Pappalardo 2016 <sup>13</sup>	Postop nausea (n)	25	1		25	4				OR: 0.22 (0.02 to 2.11)		.16
Pappalardo 2016 <sup>13</sup>	Total complications (n)	25	4		25	6				OR: 0.6 (0.15 to 2.47)		.48
Vlug 2011 <sup>14</sup> Laparoscop y	Total LOS (days)	100	5 (median)	4 to 8 (IQR)	109	6 (median)	4.5 to 9.5 (IQR)	5.7 (3.0)	6.7 (3.8)	29 (57 to02)	-1.0 (-1.9 to07)	<.05
Vlug 2011 <sup>14</sup>	Postop LOS	100	5	4 to 7	109	6	4 to 8.5	5.3 (2.3)	6.2 (3.4)	29	83	<.05

	Τ.,											
		Intervention C			Comparator I		Intervention Comparator					
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean change (95% CI)	р
Laparoscop y	(days)		(median)	(IQR)		(median)	(IQR)			(56 to02)	(-1.6 to04)	
Vlug 2011 <sup>14</sup> Laparoscop y	Reoperation rate (%)	100	10		109	10.1				OR: .99 (0.4 to 2.44)		.98
Vlug 2011 <sup>14</sup> Laparoscop y	Readmission rate (%)	100	6		109	6.4				OR: 0.93 (0.3 to 2.88)		.91
Vlug 2011 <sup>14</sup> Laparoscop y	Patients with major complications (%)	100	15		109	11				OR: 1.43 (0.63 to 3.22)		.39
Vlug 2011 <sup>14</sup> Laparoscop y	Mortality (%)	100	2		109	1.8				OR: 1.11 (0.15 to 8.13)		.92
Vlug 2011 <sup>14</sup> Open	Total LOS (days)	93	7 (median)	5 to 11 (IQR)	98	7 (median)	6 to 13 (IQR)	7.7 (4.5)	8.7 (5.2)	20 (49 to .08)	-1.0 (-2.4 to .40)	.16
Vlug 2011 <sup>14</sup> Open	Postop LOS (days)	93	6 (median)	4.5 to 10 (IQR)	98	7 (median)	6 to 10.5 (IQR)	6.8 (4.1)	7.8 (3.4)	26 (55 to02)	-1.0 (-2.08 to .08)	.07
Vlug 2011 <sup>14</sup> Open	Reoperation rate (%)	93	14		98	18.4				OR: 0.72 (0.33 to 1.57)		.41
Vlug 2011 <sup>14</sup> Open	Readmission rate (%)	93	7.5		98	7.1				OR: 1.06 (0.36 to 3.16)		.92
Vlug 2011 <sup>14</sup> Open	Patients with major complications (%)	93	20.4		98	21.4				OR: 0.94 (0.47 to 1.89)		.87
Vlug 2011 <sup>14</sup> Open	Mortality (%)	93	4.3		98	2.0				OR: 2.2 (0.39 to 12.46)		.36

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data, imputed where necessary. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). LOS=Length of stay; SE=Standard Error; IQR=Interquartile range; OR=Odds Ratio; POD=Post-operative day; SD=Standard deviation; CI=Confidence interval; Postop=Postoperative; LAR=Lower Anterior Resection; AR=Anterior Resection; n=sample size

		Intervention (			Comparator I		Intervention	Comparator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	d (95% CI)	Mean change (95% CI)	р
Anderson 2003 <sup>1</sup>	Return of gastrointestinal function (postop hours)	14	48 (median)	33 to 55 (IQR)	11	76	70 to 110 (IQR)	45.3 (18.1)	85.3 (33.9)	-1.53 (-2.43 to66)	-40.0 (-61.8 to -18.2)	<.001
Anderson 2003 <sup>1</sup>	Walked to toilet unaided (postop hours)	14	46 (median)	37 to 54 (IQR)	11	69 (median)	44 to 121 (IQR)	45.7 (14.0)	78.0 (65.3)	65 (-1.46 to .16)	-32.3 (-69.3 to 4.6)	.08
Forsmo 2016 <sup>3</sup>	Passage of first flatus (POD)	154	1 (median)	0 to 4 (range)	153	1 (median)	1 to 14 (range)					
Forsmo 2016 <sup>3</sup>	Passage of first stool (POD)	154	1 (median)	1 to 6 (range)	153	2 (median)	1 to 14 (range)					
Forsmo 2016 <sup>3</sup>	Tolerating food without nausea (POD)	154	2 (median)	0 to 9 (range)	153	1 (median)	0 to 12 (range)					
Forsmo 2016 <sup>3</sup>	Pain control with oral medication (POD)	154	2 (median)	0 to 9 (range)	153	4 (median)	0 to 16 (range)					
Forsmo 2016 <sup>3</sup>	C-reactive protein levels (mg/L)	154	121 (median)	19 to 499 (range)	153	96 (median)	7 to 454 (range)					
Garcia- Botello 2011 <sup>4</sup>	Start of liquid diet (POD)	61	0 (median)	0 to 2 (range)	58	3 (median)	1 to 5 (range)					
Garcia- Botello 2011 <sup>4</sup>	Passage of first flatus (POD)	61	1 (median)	1 to 3 (range)	58	3 (median)	1 to 6 (range)					
Garcia- Botello 2011 <sup>4</sup>	Passage of first stool (POD)	61	3 (median)	3 to 7 (range)	58	4 (median)	2 to 8 (range)					
Garcia-	Pain on POD1	61	4	1 to 9	58	5	1 to 10					

Table 2. Data for patient-reported outcomes for each study trialling an ERP intervention to improve recovery following colorectal surgery. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.

		Inter	vention		Comp	parator		Intervention	Comparator			
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	d (95% CI)	Mean change (95% CI)	р
Botello 2011 <sup>4</sup>	(VAS 1-10)		(median)	(range)		(median)	(range)					
Garcia-	Pain on POD2	61	4	1 to 8	58	4	2 to 8					
Botello 2011 <sup>4</sup>	(VAS 1-10)		(median)	(range)		(median)	(range)					
Garcia-	Pain on POD3	61	3	1 to 6	58	3	1 to 7					
Botello 2011 <sup>4</sup>	(VAS 1-10)		(median)	(range)		(median)	(range)					
Gatt 2005 <sup>5</sup>	Time out of bed	19	105	34 to	20	8	0 to 38					
	on POD1 (mins)		(median)	225 (range)		(median)	(range)					
Khoo 2007 <sup>6</sup>	Tolerating solid	35	1	0 to 6	35	4	2 to 9					
	diet (POD)		(median)	(range)		(median)	(range)					
Khoo 2007 <sup>6</sup>	Independent	35	2	1 to 10	35	4	2 to 32					
1/1 00076	mobility (POD)	25	(median)	(range)	25	(median)	(range)					
Khoo 2007 <sup>6</sup>	Passage of first	35	3	1 to $5$	35	5 (madian)	0 to $23$					
Khao 20076	Stool (POD)	25	(median)	(range)	25	(median)	(range)					
KII00 2007*	would benefit from longer stay	55	5		55	24						
	(n)											
Lee 2011 <sup>7</sup>	Fluid intake	46	6 (madian)	5 to 10.5	54	71 (madian)	48 to 195	7.2 (4.2)	70.2 (33.1)	-2.57	-63.0	<.001
Lee 2011 <sup>7</sup>	Normal diet	56		39 to	54	95	$\frac{(IQR)}{85 \text{ to}}$	428(57)	97.8 (21.7)	-3.10 -2.04)	-55.0	< 001
Let 2011	(postop hours)	50	(median)	46.5	54	(median)	113.5	42.0 (5.7)	<i>) 1.</i> 0 (21.7)	(-4.09 to -2.9)	(-61.0 to -49.0)	<.001
L ag 20117	Decesso of first	16	50	$\frac{(IQK)}{20 \text{ to}}$	51	62	$\frac{(IQK)}{41 \text{ to } 70}$	57 1 (26 0)	60.7 (28.0)	12	2.6	50
Lee 2011	flatus (postop	40	Jo (median)	59 to 74 2	34	02 (median)	(IOP)	57.1 (20.9)	00.7 (28.9)	13	-3.0 (14.8 to 7.6)	.32
	hours)		(incutail)	(IQR)		(incutail)	(IQK)			(	(-14.8 to 7.0)	
Lee 2011 <sup>7</sup>	Passage of first	46	113	76 to	54	120	86 to 145	111.0 (52.0)	117.0 (44.9)	12	-6.0	.54
	stool (postop		(median)	144		(median)	(IQR)			(52 to .27)	(-25.2 to 13.2)	
	hours)			(IQR)								
Lee 2011 <sup>7</sup>	Overall time to	46	93.5	84 to	54	127	101 to	95.8 (19.9)	122.1 (28.4)	-1.06	-26.3	<.001
	recovery (postop		(median)	110 (IOD)		(median)	138.3 (IOD)			(-1.48 to64)	(-36.2 to -16.4)	
	nours)			(IQK)			(IQK)					

		Intervention n Estimate Variance		Comp	parator		Intervention	Comparator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	d (95% CI)	Mean change (95% CI)	р
Lee 2011 <sup>7</sup>	Tolerating diet for 24 hours (postop hours)	46	67 (median)	63 to 70.5 (IQR)	54	120 (median)	98 to 127 (IQR)	66.8 (5.7)	115.0 (22.1)	-2.88 (-3.45 to - 2.32)	-48.2 (-54.8 to -41.5)	<.001
Lee 2011 <sup>7</sup>	Safe ambulation (postop hours)	46	18 (median)	14 to 20.7 (IQR)	54	21 (median)	18 to 24 (IQR)	17.6 (5.1)	21.0 (4.6)	71 (-1.11 to3)	-3.4 (-5.4 to -1.5)	<.001
Lee 2011 <sup>7</sup>	Analgesic-free (postop hours)	46	88 (median)	71.5 to 120 (IQR)	54	117 (median)	86 to 149 (IQR)	93.2 (37.1)	117.3 (48.0)	56 (96 to16)	-24.2 (-41.4 to -6.9)	<.01
Lee 2011 <sup>7</sup>	Afebrile without complications (postop hours)	46	84 (median)	84 to 108 (IQR)	54	118 (median)	90 to 117.5 (IQR)	92.0 (18.4)	108.5 (20.9)	83 (-1.24 to42)	-16.5 (-24.4 to -8.6)	<.001
Lee 2011 <sup>7</sup>	Pain (VAS score)	46	1.2	1.1	54	1.1	1.3			.08 (31 to 48)	.1 (38 to .58)	.68
Lidder 2013 <sup>8</sup>	Fit for discharge (POD)	27	7 (median)	5 to 10 (IQR)	30	8 (median)	6 to 13 (IQR)	7.3 (3.9)	9.0 (5.5)	35 (87 to .17)	-1.67 (-4.21 to .88)	.19
Mari 2014 <sup>10</sup>	First bowel movement (POD)	25	0.3	0.6	25	1.7	0.5			-2.5 (-3.25 to - 1.76)	-1.43 (-1.75 to -1.10)	<.001
Mari 2014 <sup>10</sup>	Passage of first flatus (POD)	25	0.9	0.8	25	2.1	0.9			-1.39 (-2.01 to77)	-1.2 (-1.69 to71)	<.001
Mari 2014 <sup>10</sup>	Passage of first stool (POD)	25	1.6	1.0	25	5	1.8			-2.36 (-3.09 to - 1.63)	-3.4 (-4.22 to -2.58)	<.001
Mari 2014 <sup>10</sup>	Solid diet tolerance (POD)	25	1.2	0.4	25	3.8	1.0			-3.46 (-4.35 to - 2.57)	-2.61 (-3.04 to -2.18)	<.001
Mari 2014 <sup>10</sup>	Walk at least 60m (POD)	25	1.3	0.8	25	3.6	0.5			-3.35 (-4.22 to - 2.48)	-2.25 (-2.63 to -1.87)	<.001
Mari 2016 <sup>11</sup>	Passage of flatus (POD)	40	1.5	0.6	43	2.4	0.9			-1.17 (-1.64 to7)	-1.97 (-1.23 to56)	<.001
Mari 2016 <sup>11</sup>	Solid diet tolerance (POD)	40	1.2	0.8	43	2.9	0.3			-2.85 (-3.47 to -	-1.7 (-1.96 to -1.44)	<.001

		InterventionCnEstimateVariancenNotestimateNotestimate		Com	parator		Intervention	Comparator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	d (95% CI)	Mean change (95% CI)	р
										2.24)		
Mari 2016 <sup>11</sup>	Walking of 100 metres (POD)	40	1.6	0.8	43	2.9	0.9			-1.52 (-2.01 to - 1.03)	-1.3 (-1.67 to93)	<.001
Mari 2016 <sup>11</sup>	C-reactive protein levels (mg/L)	40	52.9	29.9	43	84.2	67.9			6 (-1.04 to16)	-31.3 (-54.5 to -8.1)	<.01
Mari 2016 <sup>11</sup>	Prolactin concentrations in serum (mg/dl)	40	25.4	14.6	43	17.9	15.2			.5 (.07 to .94)	7.5 (.98 to 14.0)	<.05
Mari 2016 <sup>11</sup>	White blood cell count (/mm3)	40	9295	2587	43	10132	2929			3 (74 to .13)	-837 (-2048 to 74)	.17
Mari 2016 <sup>11</sup>	IL-6 concentrations in serum (pg/ml)	40	33.5	24.2	43	57.4	19.1			-1.09 (-1.55 to63)	-23.9 (-33.4 to -14.4)	<.001
Mari 2016 <sup>11</sup>	Cortisol concentrations (mcg/dl)	40	11.7	8.1	43	17.4	11.1			59 (-1.03 to15)	-5.7 (-9.97 to -1.43)	<.01
Mari 2016 <sup>11</sup>	Transferrin serum levels (mg/dl)	40	202	42.2	43	178	34.5			.62 (.18 to 1.06)	24.0 (7.22 to 40.8)	<.01
Mari 2016 <sup>11</sup>	Prealbumin serum levels (mg/dl)	40	14.4	5	43	13.3	4.4			.23 (2 to .67)	1.1 (95 to 3.15)	.29
Mari 2016 <sup>11</sup>	Albumin serum levels (g/dl)	40	3.12	0.3	43	3.09	0.36			.03 (4 to .46)	.03 (12 to .18)	.68
Mari 2016 <sup>11</sup>	Triglyceride serum levels (mg/dl)	40	69.55	36.2	43	63.28	17.6			.22 (21 to .65)	6.3 (-6.03 to 18.6)	.31
Pappalardo 2016 <sup>13</sup>	EORTC QLC-CR 38: score excellent/ good (n)	25	14		25	12						
Pappalardo 2016 <sup>13</sup>	EORTC QLC-CR 38: Score moderately good	25	8		25	9						

		Intervention s) n Estimate Variance CR 25 2			Comp	parator		Intervention	Comparator			
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	d (95% CI)	Mean change (95% CI)	р
	(n)											
Pappalardo 2016 <sup>13</sup>	EORTC QLC-CR 38: Score acceptable (n)	25	2		25	3						
Pappalardo 2016 <sup>13</sup>	EORTC QLC-CR 38: Score poor (n)	25	1		25	1						
Vlug 2011 <sup>14</sup> ^ Laparoscop y	Gastric retention (% remaining in stomach)	18	70 (median)	36 to 94 (IQR)	17	81 (median)	34 to 95 (IQR)	43.6 (46.7)	70.0 (49.3)	55 (-1.23 to .13)	-26.4 (-59.4 to 6.6)	.11
Vlug 2011 <sup>14</sup> ^ Laparoscop y	Colonic transit: geometric centre of intracolonic mass 48 postprandially (0- 3)* <sup>1</sup>	18	2.2 (median)	1.8 to 2.6 (IQR)	17	1.3 (median)	1.2 to 2.0 (IQR)	2.2 (0.6)	1.5 (0.6)	1.09 (.37 to 1.8)	.7 (.26 to 1.1)	<.01
Vlug 2011 <sup>14</sup> Laparoscop y	Days to fulfil discharge criteria: Pain control with Oral medication	100	2 (median)	2 to 3 (IQR)	109	3 (median)	2 to 4 (IQR)	2.3 (0.8)	3.0 (1.5)	56 (83 to28)	67 (-1.0 to34)	<.001
Vlug 2011 <sup>14</sup> Laparoscop y	Days to fulfil discharge criteria: Tolerate solid food	100	1 (median)	1 to 2 (IQR)	109	2 (median)	1 to 3 (IQR)	1.3 (0.8)	2.0 (1.5)	56 (83 to28)	67 (-1.0 to34)	<.001
Vlug 2011 <sup>14</sup> Laparoscop y	Days to fulfil discharge criteria: Absence of nausea	100	1 (median)	1 to 3 (IQR)	109	1 (median)	1 to 3 (IQR)	1.7 (1.5)	1.7 (1.5)	0 (27 to .27)	0 (41 to .41)	1.0
Vlug 2011 <sup>14</sup> Laparoscop y	Days to fulfil discharge criteria: Passage of first flatus	100	1 (median)	1 to 2 (IQR)	109	2 (median)	1 to 3 (IQR)	1.3 (0.8)	2.0 (1.5)	56 (83 to28)	67 (-1.0 to34)	<.001
Vlug 2011 <sup>14</sup> Laparoscop	Days to fulfil discharge criteria:	100	2 (median)	1 to 4 (IQR)	109	3 (median)	2 to 4 (IQR)	2.3 (2.3)	3.0 (1.5)	35 (63 to08)	67 (-1.19 to15)	<.05

		Interv	vention		Com	parator		Intervention	Comparator			
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	d (95% CI)	Mean change (95% CI)	р
У	Passage of first stool											
Vlug 2011 <sup>14</sup> Laparoscop y	Days to fulfil discharge criteria: Mobilization as preoperative	100	3 (median)	2 to 5 (IQR)	109	5 (median)	4 to 7 (IQR)	3.3 (2.3)	5.3 (2.3)	89 (-1.17 to6)	-2.0 (-2.62 to -1.38)	<.001
Vlug 2011 <sup>14</sup> Laparoscop y	Days to fulfil discharge criteria: Acceptance of discharge	100	4 (median)	3 to 6 (IQR)	109	5.5 (median)	4 to 8.5 (IQR)	4.3 (2.3)	6.0 (3.4)	58 (85 to3)	-1.67 (-2.46 to88)	<.001
Vlug 2011 <sup>14</sup> Open	Days to fulfil discharge criteria: Pain control with Oral medication	93	2 (median)	2 to 4 (IQR)	98	3 (median)	2 to 5 (IQR)	2.7 (1.5)	3.3 (2.3)	34 (63 to06)	67 (-1.22 to12)	<.05
Vlug 2011 <sup>14</sup> ^ Open	Gastric retention (% remaining in stomach)	18	58 (median)	26 to 71 (IQR)	18	81 (median)	34 to 95 (IQR)	51.7 (36.2)	63.0 (55.5)	24 (9 to .41)	-11.3 (-43.1 to 20.4)	.07
Vlug 2011 <sup>14</sup> A Open	Colonic transit: geometric centre of intracolonic mass 48 postprandially (0- 3)* <sup>1</sup>	18	1.5 (median)	1.2 to 1.9 (IQR)	18	1.1 (median)	1.0 to 1.4 (IQR)	1.5 (0.6)	1.2 (0.3)	.79 (.11 to 1.47)	.37 (.06 to .68)	<.05
Vlug 2011 <sup>14</sup> Open	Days to fulfil discharge criteria: Tolerate solid food	93	1 (median)	1 to 3 (IQR)	98	3 (median)	2 to 5 (IQR)	1.7(1.5)	3.3 (2.3)	86 (-1.16 to56)	-1.67 (-2.22 to -1.12)	<.001
Vlug 2011 <sup>14</sup> Open	Days to fulfil discharge criteria: Absence of nausea	93	2 (median)	1 to 5 (IQR)	98	1 (median)	1 to 4 (IQR)	2.7 (3.0)	2.0 (2.3)	.25 (03 to .54)	.67 (09 to 1.42)	.07
Vlug 2011 <sup>14</sup> Open	Days to fulfil discharge criteria: Passage of first flatus	93	1 (median)	1 to 3 (IQR)	98	2 (median)	1 to 3 (IQR)	1.7 (1.5)	2.0 (1.5)	22 (5 to .07)	33 (76 to .10)	.17

		Inter	vention		Com	parator		Intervention	Comparator			
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	d (95% CI)	Mean change (95% CI)	р
Vlug 2011 <sup>14</sup> Open	Days to fulfil discharge criteria: Passage of first stool	93	3 (median)	2 to 4 (IQR)	98	4 (median)	3 to 6 (IQR)	3.0 (1.5)	4.3 (2.3)	69 (98 to4)	-1.33 (-1.88 to78)	<.001
Vlug 2011 <sup>14</sup> Open	Days to fulfil discharge criteria: Mobilisation as preoperative	93	4 (median)	3 to 7 (IQR)	98	6 (median)	5 to 8 (IQR)	4.7 (3.0)	6.3 (2.3)	63 (92 to34)	-1.67 (-2.42 to91)	<.001
Vlug 2011 <sup>14</sup> Open	Days to fulfil discharge criteria: Acceptance of discharge	93	5.5 (median)	4 to 9 (IQR)	98	7 (median)	5 to 12 (IQR)	6.2 (3.8)	8.0 (5.3)	4 (68 to11)	-1.83 (-3.15 to52)	<.05

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs, imputed where necessary. P-values are from independent samples t-tests. ^data from van Bree 2011; \*<sup>1</sup> score correlates with location: 0=small intestine, 1=proximal colon, 2=distal colon, 3=stool; HADS=Hospital Anxiety and Depression Scale; IQR=Interquartile Range; VAS=Visual Analogue Scale; EORTC=European Organisation for Research and Treatment of Cancer; LASA=Longitudinal Ageing Study Amsterdam; QoL=Quality of Life; POD=Post-operative Day; SE=Standard Error; SF36=Short Form 36; n=sample size

		Inter	vention		Com	parator		Intervention	Comparator			
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean change (95% CI)	р
Carli 2010 <sup>15</sup>	Postop LOS (days)	21	7.4	6.5 (SE)	53	6.6	3.6 (SE)	7.4 (48.2)	6.6 (26.7)	.02 (36 to .40)	.8 (-14.1 to 15.7)	.93
Carli 2010 <sup>15</sup>	Patients with a complication (%)	21	39		53	33				OR: 1.3 (0.46 to 3.7)		.63
Dronkers 2010 <sup>16</sup>	Postop LOS (days)	21	16.2	11.5	20	21.6	23.7			29 (91 to .32)	-5.4 (-17.1 to 6.3)	.36
Dronkers 2010 <sup>16</sup>	Patients with postop complications (%)	21	45		20	38				OR: 1.33 (0.38 to 4.64)		.65
Gillis 2014 <sup>17</sup>	LOS (primary hospitalisation, days)	38	4 (median)	3 to 5 (IQR)	39	4 (median)	3 to 7 (IQR)	4.0 (1.5)	4.7 (3.1)	27 (72 to .17)	67 (-1.78 to .44)	.21
Gillis 2014 <sup>17</sup>	Total stay, including readmissions (days)	38	4 (median)	3 to 6 (IQR)	39	5 (median)	3 to 9 (IQR)	4.3 (2.3)	5.7 (4.6)	37 (82 to .09)	-1.33 (-3.0 to .33)	.10
Gillis 2014 <sup>17</sup>	30 day emergency department visits (n)	38	6		39	9				OR: 0.63 (0.2 to 1.97)		.42
Gillis 2014 <sup>17</sup>	Readmissions <30 days (%)	38	15.8		39	12.9				OR: 1.28 (0.35 to 4.59)		.71
Gillis 2014 <sup>17</sup>	Patients with complications <30 days (%)	38	32		39	44				OR: 0.6 (0.24 to 1.52)		.28

Table 3. Data for clinical outcomes for each study trialling a Prehabilitation intervention to improve recovery following colorectal surgery. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data, imputed where necessary. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). LOS=Length of stay; OR=Odds Ratio; SE=Standard Error; IQR=Interquartile range; POD=Post-operative day; SD=Standard deviation; CI=Confidence interval; ERP=Enhanced Recovery Protocol; Prehab=Prehabilitation; Postop=Postoperative; n=sample size

		Inter	vention		Com	parator		Intervention	Comparator			
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	d (95% CI)	Mean change (95% CI)	р
Carli 2010 <sup>15</sup>	6MWT (min)	58	463.6	18.5 (SE)	54	502.8	15.8 (SE)	463.6 (140.9)	502.8 (116.1)	3 (68 to .07)	-39.2 (-87.7 to 9.3)	.11
Carli 2010 <sup>15</sup>	HADS Anxiety (raw score)	58	5.2	0.5 (SE)	54	5.7	0.6 (SE)	5.2 (3.8)	5.7 (4.4)	12 (49 to .25)	5 (-2.04 to 1.04)	.52
Carli 2010 <sup>15</sup>	HADS Depression (raw score)	58	3.2	0.4 (SE)	54	3.4	0.5 (SE)	3.2 (3.0)	3.4 (3.7)	06 (43 to .31)	2 (-1.46 to 1.06)	.88
Carli 2010 <sup>15</sup>	Peak VO2 (ml/min)	58	1529	88 (SE)	54	1511	84 (SE)	1529 (670.2)	1511 (617.3)	.03 (34 to .4)	18.0 (-223.8 to 259.8)	.88
Carli 2010 <sup>15</sup>	Physical activity (hours/week)	45	8.3	6.2	42	6	4.8			.42 (01 to .84)	2.3 (08 to 4.68)	.06
Dronkers 2010 <sup>16</sup>	Timed up and go (s)	20	7.8	3.3	19	6.6	1.2			.49 (15 to 1.13)	1.2 (43 to 2.83)	.14
Dronkers 2010 <sup>16</sup>	Chair rise time test (s)	20	26.6	6.2	19	21.2	6.1			.88 (.22 to 1.54)	5.4 (1.41 to 9.39)	<.01
Dronkers 2010 <sup>16</sup>	Maximal Inspiratory Pressure (cmH2O)	20	92.0	26.0	19	98.0	26.0			23 (86 to .4)	-6.0 (-22.9 to 10.9)	.48
Dronkers 2010 <sup>16</sup>	Respiratory Muscle analyser energy (J)	20	404.0	349.0	19	305.0	323.0			.29 (34 to .93)	99.0 (-119.5 to 317.5)	.29
Dronkers 2010 <sup>16</sup>	LASA Physical Activity questionnaire: Energy expended (kcal/day)	20	980.0	771.0	19	1657.0	3400.0			27 (9 to .36)	-677.0 (-2257.5 to 903.6)	.39
Dronkers 2010 <sup>16</sup>	LASA Physical Activity questionnaire:	20	236.0	157.0	19	280.0	399.0			14 (77 to .49)	-44.0 (-238.8 to 150.8)	.65

 Table 4. Data for patient-reported outcomes for each study trialling a Prehabilitation intervention to improve recovery following colorectal surgery.

 Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.

		Inter	vention		Com	parator		Intervention	Comparator			
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	d (95% CI)	Mean change (95% CI)	р
	Activity in past 14 days (mins/day)											
Dronkers 2010 <sup>16</sup>	Physical Work Capacity (O <sub>2</sub> mL/kg/min)	20	27.6	6.5	19	32.9	6.9			79 (-1.44 to14)	-5.3 (-9.64 to95)	<.05
Dronkers 2010 <sup>16</sup>	Abbreviated Fatigue Questionnaire (raw score)	20	12.7	6.6	19	8.80	4.30			.70 (.06 to 1.35)	3.9 (.26 to 7.54)	<.05
Dronkers 2010 <sup>16</sup>	EORTC QoL Questionnaire: global health (raw score)	20	72.0	19.0	19	68.0	18.0			.22 (41 to .85)	4.0 (-8.0 to 16.0)	.50
Dronkers 2010 <sup>16</sup>	EORTC QoL Questionnaire: function (raw score)	20	413.0	64.0	19	425.0	67.0			18 (81 to .45)	-12.0 (-54.5 to 30.5)	.57
Dronkers 2010 <sup>16</sup>	EORTC QoL Questionnaire: symptoms (raw score)	20	119.0	98.0	19	155.0	117.0			33 (97 to .3)	-36.0 (-105.9 to 33.9)	.30
Gillis 2014 <sup>17</sup>	6MWT (m)	38	25.2 (mean change from baseline)	50.2	39	-16.4 (mean change from baseline)	46					
Gillis 2014 <sup>17</sup>	CHAMPS questionnaire (hours)	38	81.2	101	39	61.7	125.6			.17 (28 to .62)	19.5 (-32.3 to 71.3)	.46
Gillis 2014 <sup>17</sup>	SF-36 physical function (raw score)	38	73.5	25	39	72.6	29.7			.03 (41 to .48)	.9 (-11.6 to 13.4)	.89
Gillis 2014 <sup>17</sup>	SF-36 role physical (raw score)	38	62.3	44.3	39	56.6	50.4			.12 (33 to .57)	5.7 (-15.9 to 27.3)	.60

		Intervention n Estimate Variance		Com	parator		Intervention	Comparator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	d (95% CI)	Mean change (95% CI)	р
Gillis 2014 <sup>17</sup>	SF-36 bodily pain (raw score)	38	74.7	22.6	39	73.6	25.3			.05 (4 to .49)	1.1 (-9.80 to 12.0)	.84
Gillis 2014 <sup>17</sup>	SF-36 general health (raw score)	38	66.4	22.8	39	60	25.8			.26 (19 to .71)	6.4 (-4.66 to 17.5)	.25
Gillis 2014 <sup>17</sup>	SF-36 vitality (raw score)	38	60.3	22.7	39	59.2	23.4			.05 (4 to .49)	1.1 (-9.4 to 11.6)	.83
Gillis 2014 <sup>17</sup>	SF-36 social functioning (raw score)	38	72.3	28.8	39	75.4	31.9			1 (55 to .34)	-3.1 (-16.9 to 10.7)	.66
Gillis 2014 <sup>17</sup>	SF-36 role emotional (raw score)	38	62.8	48.8	39	53.4	49.8			.19 (26 to .64)	9.4 (-13.0 to 31.8)	.41
Gillis 2014 <sup>17</sup>	SF-36 mental health (raw score)	38	71.6	21.5	39	69.6	24.8			.09 (36 to .53)	2.0 (-8.55 to 12.5)	.71
Gillis 2014 <sup>17</sup>	HADS Anxiety (raw score)	38	5.6	3.9	39	5.9	4.7			07 (52 to .38)	3 (-2.26 to 1.67)	.76
Gillis 2014 <sup>17</sup>	HADS Depression (raw score)	38	3.2	3.1	39	3.6	4.6			10 (55 to .34)	4 (-2.19 to 1.39)	.66

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs, imputed where necessary. P-values are from independent samples t-tests. 6MWT=6 Minute Walk Test; HADS=Hospital Anxiety and Depression Scale; IQR=Interquartile Range; VAS=Visual Analogue Scale; EORTC=European Organisation for Research and Treatment of Cancer; LASA=Longitudinal Ageing Study Amsterdam; QoL=Quality of Life; POD=Post-operative Day; SE=Standard Error; n=sample size; CHAMPS=Community Healthy Activities Model Programme for Seniors; SF-36=Short Form 36

		Interv	ention		Comp	parator				
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
Borgwardt 2009 <sup>18</sup>	LOS (days)	17	1 (median)	1 to 3 (range)	23	6 (median)	4 to 7 (range)			
Borgwardt 2009 <sup>18</sup>	Rehospitalisation within 3 months (n)	17	0		23	0				
Borgwardt 2009 <sup>18</sup>	Phone contact with a GP (n)	17	4		23	2		OR: 3.23 (0.52 to 20.2)		.19
Borgwardt 2009 <sup>18</sup>	Contact with a nurse (n)	17	4		23	6		OR: 0.87 (0.2 to 3.74)		.85
Larsen 2008 <sup>19</sup>	Total LOS (days)	45	4.9	2.4	42	7.8	2.1	-1.28 (-1.75 to82)	-2.9 (-3.89 to -1.94)	<.001
Larsen 2008 <sup>19</sup>	Readmissions (n)	45	2		41	1		OR: 1.86 (0.16 to 21.32)		.61
Pour 2007 <sup>20</sup>	LOS (days)	46	3.5	2 to 5 (range)	48	4.2	3 to 8 (range)			
Pour 2007 <sup>20</sup>	Short term complications (n)	46	0		48	0				1.0
Reilly 2005 <sup>21</sup>	LOS (days)	21	1.5	1 to 5 (range)	20	4.3	1 to 6 (range)			
Reilly 2005 <sup>21</sup>	Patients who developed complications post discharge (n)	21	3		20	1		OR: 3.17 (0.3 to 33.31)		.32
Reilly 2005 <sup>21</sup>	Major complications (n)	32	2		20	1		OR: 0.95 (0.06 to 16.29)		.97
Siggeirsdottir 2005 <sup>22</sup>	LOS (days)	27	6.4	2.4	23	10	3.5	-1.22 (-1.83 to61)	-3.6 (-5.29 to -1.91)	<.001
Siggeirsdottir 2005 <sup>22</sup>	Readmissions (n)	27	0		23	1				.27
Siggeirsdottir 2005 <sup>22</sup>	Total complications (n)	27	5		23	11		OR: 0.25 (0.07 to 0.88)		<.05

Table 5. Data for clinical outcomes for each study trialling an ERP intervention to improve recovery following lower limb arthroplasty. Reported values are presented (mean and standard deviation (SD) unless indicated).

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data, imputed where necessary. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). LOS=Length of stay; SD=Standard deviation; CI=Confidence interval; OR=Odds Ratio; n=sample size

		Interv	ention		Comp	parator				
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	d (95% CI)	Mean change (95% CI)	р
Borgwardt 2009 <sup>18</sup>	Knee joint function	17	95	64 to 100	23	90	35 to 100			
	(raw score)		(median)	(range)		(median)	(range)			
Borgwardt 2009 <sup>18</sup>	Ability to walk and	17	100	70 to 100	23	93	35 to 100			
	climb stairs (raw		(median)	(range)		(median)	(range)			
1	score)									
Borgwardt 2009 <sup>18</sup>	Number who had lower limb weakness	17	0		23	11				
Borgwardt 2009 <sup>18</sup>	Pain at mobilisation	17	1	0 to 2.5	23	5	0 to 7.5			
	(VAS 1 to 10)		(median)	(range)		(median)	(range)			
Borgwardt 2009 <sup>18</sup>	Number who were confident or very confident	17	13		23	18				
Borgwardt 2009 <sup>18</sup>	Number very satisfied with operation and perioperative period	17	11		23	14				
Larsen 2008 <sup>19</sup>	Patients well at 3 months (n)	45	28		42	15				
Larsen 2008 <sup>19</sup>	EQ-5D (index score)	45	0.87	0.15	42	0.79	0.2	.50 (.07 to .93)	.08 (.004 to .16)	<.05
Pour 2007 <sup>20</sup>	Walking status at discharge (n independent or supervised)	46	39		48	29				
Pour 2007 <sup>20</sup>	Walking status at discharge (n assisted or contact guard needed)	46	7		48	19				
Pour 2007 <sup>20</sup>	Walking aid use at discharge (n single point cane)	46	4		48	1				
Pour 2007 <sup>20</sup>	Walking aid use at discharge (n axillary	46	10		48	8				

 Table 6. Data for patient-reported outcomes for each study trialling an ERP intervention to improve recovery following lower limb arthroplasty.

 Reported values are presented (mean and standard deviation (SD) unless indicated).

		Interv	vention		Com	parator				
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	d (95% CI)	Mean change (95% CI)	р
	crutches)								, , , , , , , , , , , , , , , , , , ,	
Pour 2007 <sup>20</sup>	Walking aid use at discharge (n rolling walker)	46	10		48	12				
Pour 2007 <sup>20</sup>	Walking aid use at discharge (n standard walker)	46	22		48	27				
Pour 2007 <sup>20</sup>	Walking distance at discharge (m)	46	35	7 to 91.5 (range)	48	24.3	3.5 to 91.5 (range)			
Pour 2007 <sup>20</sup>	LASA PAQ: Energy (raw score)	46	8	5 to 10 (range)	48	7	2 to 9.8 (range)			
Pour 2007 <sup>20</sup>	LASA PAQ: Daily activity (raw score)	46	8.3	3 to 10 (range)	48	7	3 to 10 (range)			
Pour 2007 <sup>20</sup>	LASA PAQ: Quality of Life (raw score)	46	8.4	3 to 10 (range)	48	7.5	3 to 10 (range)			
Pour 2007 <sup>20</sup>	Harris Hip score (raw score)	46	87.6	51.4 to 100 (range)	48	86.2	55.7 to 95.7 (range)			
Pour 2007 <sup>20</sup>	SF-36: Physical health (raw score)	46	71.2	35.6 to 95.9 (range)	48	63.6	24.2 to 95.9 (range)			
Pour 2007 <sup>20</sup>	SF-36: Mental health (raw score)	46	80.8	41.6 to 98 (range)	48	72.3	24.6 to 95.2 (range)			
Pour 2007 <sup>20</sup>	WOMAC (raw score)	46	12.4	0 to 51 (range)	48	13.5	0 to 32 (range)			
Pour 2007 <sup>20</sup>	Lower extremity functional score (raw score)	46	9.8	6 to 12 (range)	48	9.2	7 to 11 (range)			
Reilly 2005 <sup>21</sup>	Oxford Knee Assessment (raw score)	21	43.7	3.7	20	42.2	7.1	.27 (-0.35 to .88)	1.5 (-2.05 to 5.05)	.40
Reilly 2005 <sup>21</sup>	AKSS Objective (raw score)	21	88.4	10.4	20	89.4	17.5	07 (68 to .54)	-1.0 (-10.0 to 8.04)	.82
Reilly 2005 <sup>21</sup>	AKSS Functional (raw score)	21	90.9	11.7	20	90	13.3	.07 (54 to .68)	.9 (-7.00 to 8.80)	.82

		Interv	vention		Com	parator				
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	d (95% CI)	Mean change (95% CI)	р
Reilly 2005 <sup>21</sup>	Knee flexion ROM (degrees)	21	124.7	5.5	20	119.8	6.8	.79 (.16 to 1.43)	4.9 (1.0 to 8.8)	<.05
Reilly 2005 <sup>21</sup>	Knee extension ROM (degrees)	21	-3.10	3.5	20	-2.3	3.5	23 (84 to .39)	8 (-3.01 to 1.41)	.42
Siggeirsdottir 2005 <sup>22</sup>	Oxford Hip Score (raw score)	27	19	6.3	21	24	9	66 (-1.24 to07)	-5.0 (-9.45 to55)	<.05
Siggeirsdottir 2005 <sup>22</sup>	Harris Hip Score (raw score)	27	76 (median)	56 to 93 (range)	27	71 (median)	31 to 83 (range)			

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs, imputed where necessary. P-values are from independent samples t-tests. 6MWT=6 Minute Walk Test; HADS=Hospital Anxiety and Depression Scale; VAS=Visual Analogue Scale; ROM=Range of Movement; AKSS=American Knee Society Score; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index; SF-36=Short Form 36; LASA PAQ=Longitudinal Ageing Study Amsterdam Physical Activity Questionnaire; n=sample size

		Interv	ention		Comp	arator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
Crowe 2003 <sup>23</sup>	LOS (days)	65	6.55	4.2	68	10.5	14.2	37 (71 to03)	-3.95 (-7.58 to32)	<.05
Crowe 2003 <sup>23</sup>	Total complications (n)	65	7		68	22		OR: 0.25 (0.1 to 0.64)		<.01
Hoogeboom 2012 <sup>24</sup>	LOS (days)	10	6 (median)	5 to 22 (range)	11	6 (median)	4 to 7 (range)			
Hoogeboom 2012 <sup>24</sup>	Total complications (n)	10	2		11	0				.12
Huang 2012 <sup>25</sup>	LOS (days)	126	7.0	2.0	117	8.0	1.0	63 (88 to37)	-1.0 (-1.40 to60)	<.001
Huang 2012 <sup>25</sup>	Blood transfusion (%)	126	11.9		117	8.5		OR: 1.45 (0.62 to 3.38)		.38
Huang 2012 <sup>25</sup>	Infection (%)	126	1.6		117	0.9		OR: 1.79 (0.17 to 19.16)		.63
Huang 2012 <sup>25</sup>	Deep vein thrombosis (%)	126	4		117	2.6		OR: 1.56 (0.37 to 6.63)		.54
Huang 2012 <sup>25</sup>	Total complications (%)	126	17.5		117	12		OR: 1.56 (0.76 to 3.2)		1.0
McGregor 2004 <sup>26</sup>	LOS (days)	19	15		20	18				
Williamson 2007 <sup>27</sup>	LOS (days)	60	6.49	1.99	61	6.6	2.62	04 (40 to .31)	11 (95 to .73)	.80

Table 7. Data for clinical outcomes for each study trialling a Prehabilitation intervention to improve recovery following lower limb arthroplasty. Reported values are presented (mean and standard deviation (SD) unless indicated).

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). OR=Odds Ratio; LOS=Length of Stay; SD=Standard Deviation; CI=Confidence Interval; n=sample size

		Interv	vention		Com	parator				
Study, intervention	Outcome (units)	n	Mean	SD	n	Mean	SD	d (95% CI)	Mean change (95% CI)	р
Crowe 2003 <sup>23</sup>	Days to meet specific discharge criteria: independently get out of bed	65	4.71	3.4	68	5.87	3.2	36 (71 to02)	-1.16 (-2.29 to03)	<.05
Crowe 2003 <sup>23</sup>	Days to meet specific discharge criteria: joint flexion	65	5.12	5.4	68	6.54	3.5	31 (65 to .03)	-1.42 (-2.97 to .13)	.07
Crowe 2003 <sup>23</sup>	Days to meet specific discharge criteria: walk 30 metres	65	5.27	5.9	68	6.75	7.5	22 (56 to .12)	-1.48 (-3.80 to .84)	.21
Crowe 2003 <sup>23</sup>	Days to meet specific discharge criteria: climb stairs	65	5.83	6.6	68	6.38	3.4	12 (46 to .23)	55 (-2.34 to 1.24)	.54
Crowe 2003 <sup>23</sup>	Days to meet specific discharge criteria: equipment ready for discharge	65	1.95	5.6	68	6.06	4	85 (-1.20 to49)	-4.11 (-5.77 to -2.45)	<.001
Crowe 2003 <sup>23</sup>	Days to meet specific discharge criteria: meals planned for discharge	65	1.37	1.3	68	5.8	4.5	-1.32 (-1.69 to94)	-4.43 (-5.58 to -3.28)	<.001
Crowe 2003 <sup>23</sup>	Days to meet all discharge criteria	65	4.71	3.4	68	5.87	3.2	43 (77 to08)	-2.59 (-4.69 to49)	<.05
Hoogeboom 2012 <sup>24</sup>	6MWT (m)	10	363	126.3	10	342.7	133.7	.16 (72 to 1.03)	20.3 (-102 to 143)	.73
Hoogeboom 2012 <sup>24</sup>	Timed up and go test (s)	10	9.6	2.8	10	13.4	11.5	45 (-1.34 to .43)	-3.8 (-11.7 to 4.06)	.32
Hoogeboom 2012 <sup>24</sup>	Chair rise time (s)	10	15	5.8	10	17.4	5.9	41 (-1.30 to .48)	-2.4 (-7.90 to 3.10)	.37
Hoogeboom 2012 <sup>24</sup>	PWC-170 ergometer test (raw score)	10	103.6	74.5	10	120.7	63.3	25 (-1.13 to .63)	-17.1 (-82.0 to 47.8)	.59
Hoogeboom	Hand Grip Strength	10	289.6	105.8	10	317.9	85.1	29	-28.3	.52

Table 8. Data for patient-reported outcomes for each study trialling a Prehabilitation intervention to improve recovery from lower limb arthroplasty. Mean and standard deviation (SD) are presented throughout.

		Intervention			Comp	arator				
Study, intervention	Outcome (units)	n	Mean	SD	n	Mean	SD	d (95% CI)	Mean change (95% CI)	р
2012 <sup>24</sup>	(raw score)							(-1.18 to .59)	(-119 to 61.9)	
Hoogeboom 2012 <sup>24</sup>	Hand Grip Strength (2 s mean score)	10	243.7	92.2	10	283.5	83.3	45 (-1.34 to .44)	-39.8 (-122 to 42.8)	.32
Hoogeboom 2012 <sup>24</sup>	LASA PAQ (kcal/minutes/kg)	10	0.04	0.01	10	0.04	0.01	.0 (88 to .88)	.0 (01 to .01)	1.0
Huang 2012 <sup>25</sup>	Knee range of motion	126	30	11	117	30	12	.0 (25 to .25)	.0 (-2.91 to 2.91)	1.0
Huang 2012 <sup>25</sup>	Knee pain (VAS 1-10)	126	4.5	1.3	117	4.4	1.2	.08 (17 to .33)	.1 (22 to .42)	.53
Huang 2012 <sup>25</sup>	Ambulation status (% ambulating by day 5)	117	81.2		126	85.7				
McGregor 2004 <sup>26</sup>	Pain (VAS 1-10)	19	7.8	1.5	20	7.6	2	.11 (52 to .74)	.2 (95 to 1.35)	.73
McGregor 2004 <sup>26</sup>	WOMAC Pain (raw score)	19	10.2	2.7	20	10.3	4.1	03 (66 to .60)	1 (-2.37 to 2.17)	.93
McGregor 2004 <sup>26</sup>	WOMAC Stiffness (raw score)	19	4.3	1.3	20	4.1	1.7	.13 (50 to .76)	.2 (79 to 1.19)	.68
McGregor 2004 <sup>26</sup>	WOMAC Function (raw score)	19	35.8	12	20	41	10	47 (-1.11 to .17)	-5.2 (-12.4 to 1.95)	.15
McGregor 2004 <sup>26</sup>	Harris Hip score (raw score)	19	45.4	11.5	20	43.2	16.2	.16 (47 to .78)	2.2 (-6.96 to 11.4)	.62
McGregor 2004 <sup>26</sup>	Barthel ADL (raw score)	19	19.2	1.3	20	19	1.3	.15 (48 to .78)	.2 (64 to 1.04)	.63
Williamson 2007 <sup>27</sup>	Oxford Knee Score (raw score)	60	28.3	9.78	61	26.7	7.45	.18 (17 to .54)	1.6 (-1.53 to 4.73)	.31
Williamson 2007 <sup>27</sup>	Time to walk 50 m (s)	60	46.6	11.4	61	44.1	6.91	.27 (09 to .62)	2.5 (89 to 5.89)	.15
Williamson 2007 <sup>27</sup>	Pain (VAS 1-10)	60	3.86	2.59	61	3.95	2.59	04 (39 to .32)	09 (-1.02 to .84)	.85
Williamson 2007 <sup>27</sup>	WOMAC (raw score)	60	26.0	17.7	61	24.6	16.8	.08 (27 to .44)	1.4 (-4.81 to 7.61)	.66
Williamson 2007 <sup>27</sup>	HADS Anxiety (raw score)	60	4.26	4.04	61	2.42	2.39	.58 (.21 to .94)	1.84 (.65 to 3.03)	<.01

		Inter	Intervention			parator				
Study, intervention	Outcome (units)	n	Mean	SD	n	Mean	SD	d (95% CI)	Mean change (95% CI)	р
Williamson 2007 <sup>27</sup>	HADS Depression (raw score)	60	3.43	2.54	61	3.68	2.93	11 (47 to .25)	25 (-1.24 to .74)	.62

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs. P-values are from independent samples t-tests . 6MWT=6 Minute Walk Test; HADS=Hospital Anxiety and Depression Scale; VAS=Visual Analogue Scale; ROM=Range of Movement; AKSS=American Knee Society Score; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index; SF-36=Short Form 36; LASA PAQ=Longitudinal Ageing Study Amsterdam Physical Activity Questionnaire; n=sample size

		Inter	vention		Com	parator		Intervention	Comparator			
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
den Hertog 2012 <sup>28</sup>	LOS (days)	69	6.75		71	13.2						
den Hertog 2012 <sup>28</sup>	Procedure-related complications (n)	69	8		71	12				OR: 0.64 (0.25 to 1.69)		.37
den Hertog 2012 <sup>28</sup>	WOMAC (raw score, Per protocol)	69	271.5 (median)	240.2 to 302.7 (95% CI)	71	345.4 (median)	312.3 to 378.6 (95% CI)	271.5 (47.3)	345.4 (50.2)	-1.52 (-1.89 to - 1.14)	-74.0 (-90.3 to -57.6)	<.001
den Hertog 2012 <sup>28</sup>	WOMAC (raw score, ITT cohort)	74	275.5 (median)	245.3 to 305.7 (95% CI)	73	345.7 (median)	313.2 to 378.3 (95% CI)	275.5 (45.6)	345.7 (49.3)	-1.48 (-1.85 to - 1.11)	-70.2 (-85.7 to -54.8)	<.001
Vesterby 2017 <sup>29</sup>	LOS (days)	36	1 (median)	1 to 5 (range)	36	2 (median)	1 to 4 (range)					
Vesterby 2017 <sup>29</sup>	Unplanned telephone calls from patient/ patient (n)	36	0.92	0.6 to 0.7 (range)	36	1.5	1.1 to 1.9 (range)			OR: 0.6 (0.04 to 8.43)		.70
Vesterby 2017 <sup>29</sup>	Unplanned extra visits to hospital/ patient (n)	36	0.17	-0.01 to 0.3 (range)	36	0.31	.04 to .57 (range)			OR: 0.55 (0 to 206.16)		.84
Vesterby 2017 <sup>29</sup>	Readmissions/ patient (n)	36	0.03	-0.03 to 0.08 (range)	36	0						

Table 9. Data for all outcomes for studies trialling Rehabilitation interventions to improve recovery from lower limb arthroplasty. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data, imputed where necessary. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). OR=Odds Ratio; LOS=Length of Stay; CI=Confidence Interval; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index; n=sample size

		Inter	vention		Com	parator		Intervention	Comparator			
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
Huddleston 2004 <sup>30</sup>	LOS (unadjusted) (days)	232	5.6		237	5.7						
Huddleston 2004 <sup>30</sup>	LOS (adjusted) (days)	232	5.1		237	5.6						
Huddleston 2004 <sup>30</sup>	Incidence of complications overall (%)	232	38.4		237	50.2				OR: 0.62 (0.43 to 0.89)		<.05
Huddleston 2004 <sup>30</sup>	Incidence of minor complications (%)	232	30.2		237	44.3				OR: 0.54 (0.37 to 0.8)		<.01
Huddleston 2004 <sup>30</sup>	Incidence of intermediate complications (%)	232	6.9		237	4.6				OR: 1.54 (0.7 to 3.39)		.28
Huddleston 2004 <sup>30</sup>	Incidence of major complications (%)	232	1.3		237	1.3				OR: 1 (0.2 to 4.94)		1.0

Table 10. Data for all outcomes for the one study trialling a Staff Mix intervention to improve recovery from lower limb arthroplasty. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data, imputed where necessary. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). OR=Odds Ratio; LOS=Length of Stay; n=sample size

		Intervention		Com	parator		Intervention	Comparator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
Arthur 2000 <sup>31</sup>	Time until order for discharge from ICU (h)	123	19.7 (median)	15.9 to 23.3 (IQR)	123	21.2 (median)	18.5 to 39.6 (IQR)	19.6 (5.5)	26.4 (15.8)	57 (83 to32)	-6.80 (-9.80 to -3.82)	<.001
Arthur 2000 <sup>31</sup>	Actual time in ICU (h)	123	24.7 (median)	21.7 to 41.9 (IQR)	123	26.7 (median)	22.8 to 46.5 (IQR)	29.4 (15.1)	32.0 (17.8)	16 (41 to .09)	-2.59 (-6.74 to 1.56)	.22
Arthur 2000 <sup>31</sup>	Time spent in the hospital after surgery (days)	123	5 (median)	5 to 6 (IQR)	123	6 (median)	5 to 7 (IQR)	5.3 (0.8)	6.0 (1.5)	56 (82 to31)	67 (96 to37)	<.001
Arthur 2000 <sup>31</sup>	Total time in hospital (days)	123	6 (median)	5 to 7 (IQR)	123	7 (median)	6 to 8 (IQR)	6.0 (1.5)	7.0 (1.5)	67 (-0.92 to41)	-1.0 (-1.37 to .62)	<.001
Furze 2009 <sup>32</sup>	LOS (days)	100	7.61	2.69	104	8.24	4.96			16 (43 to .12)	63 (-1.74 to .48)	.26
Furze 2009 <sup>32</sup>	No. of visits to NHS GP during 8 week follow up = 0 (%)	100	75		104	78.9				OR: 0.8 (0.42 to 1.55)		.51
Furze 2009 <sup>32</sup>	No. of visits to NHS GP during 8 week follow up = 1-2 (%)	100	21		104	18.3				OR: 1.19 (0.6 to 2.38)		.62
Furze 2009 <sup>32</sup>	No. of visits to NHS GP during 8 week follow up = 3 or above (%)	100	4		104	2.9				OR: 1.4 (0.31 to 6.43)		.66
Furze 2009 <sup>32</sup>	No. admissions to NHS hospital during 8 week follow up = $0$ (%)	100	99		104	97.1				OR: 2.94 (0.3 to 28.75)		.33
Furze 2009 <sup>32</sup>	No. admissions to NHS hospital	100	1		104	2.9				OR: 0.34 (0.03 to 3.33)		.33

Table 11. Data for clinical outcomes for each study trialling a Prehabilitation intervention to improve recovery after cardiac surgery. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.

		Inter	Intervention		Com	parator		Intervention	Comparator			
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
	during 8 week follow up = 1 (%)											
Furze 2009 <sup>32</sup>	Non-fatal cardiac events (n)	100	1		104	2				OR: 0.52 (0.05 to 5.77)		.58
Furze 2009 <sup>32</sup>	Deaths (n)	100	1		104	1				OR: 1.04 (0.06 to 16.86)		.98
Goodman 2008 <sup>33</sup>	LOS (days)	91	8.5 (median)	6.88 to 10.13 (IQR)	90	9 (median)	7.5 to 10.5 (IQR)	8.5 (2.4)	9 (2.3)	21 (5 to .08)	50 (-1.19 to .19)	.16
Rosenfeldt 2011 <sup>34</sup>	LOS (days)	60	6 (median)	5 to 8 (range)	57	6 (median)	5 to 8 (range)					

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data, imputed where necessary. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). OR=Odds Ratio; LOS=Length of stay; SD=Standard deviation; CI=Confidence interval; ICU=Intensive Care Unit; IQR=Interquartile range; n=sample size

		Interv	ention		Comp	arator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	d (95% CI)	Mean change (95% CI)	р
Arthur 2000 <sup>31</sup>	SF-36: Physical role subscale (Mean change from baseline)	111	9.46	34.39	109	-2.06	33.7	.34 (07 to6)	11.5 (-2.47 to 20.6)	<.05
Arthur 2000 <sup>31</sup>	SF-36: Physical functioning subscale (Mean change from baseline)	111	-1.17	18.46	109	-6.56	20.12	.28 (01 to54)	5.39 (26 to 10.5)	<.05
Arthur 2000 <sup>31</sup>	SF-36: General health subscale (Mean change from baseline)	111	8.22	18.2	109	4.14	18.78	.22 (04 to .49)	4.08 (83 to 8.90)	.10
Arthur 2000 <sup>31</sup>	SF-36: Bodily pain subscale (Mean change from baseline)	111	3.58	22.24	109	4.11	20.54	02 (294 to .24)	53 (-6.22 to 5.16)	.85
Arthur 2000 <sup>31</sup>	SF-36: Physical composite summary score (Mean change from baseline)	111	1.55	7.48	109	-1.46	7.81	.39 (13 to .66)	3.01 (98 to -5.04)	<.01
Arthur 2000 <sup>31</sup>	SF-36: Vitality subscale (Mean change from baseline)	111	-0.95	18.46	109	-1.19	15.48	.01 (25 to .28)	.24 (-4.29 to 4.77)	.92
Arthur 2000 <sup>31</sup>	SF-36: Social functioning subscale (Mean change from baseline)	111	4.5	24.7	109	0.92	24.1	.15 (12 to .41)	3.58 (-2.91 to 10.1)	.28
Arthur 2000 <sup>31</sup>	SF-36: Emotional role subscale (Mean change from baseline)	111	7.51	45.32	109	16.82	44.82	21 (47 to .06)	-9.31 (-21.3 to 2.67)	.12
Arthur 2000 <sup>31</sup>	SF-36: Mental health subscale (Mean change from baseline)	111	2.05	18.52	109	0.77	17.11	.07 (19 to34)	1.28 (-3.46 to 6.02)	.60
Arthur 2000 <sup>31</sup>	SF-36: Mental composite summary	111	1.54	10.55	109	2.93	9.15	14 (41 to .12)	-1.39 (-4.01 to 1.24)	.30

Table 12. Data for patient-reported outcomes for each study trialling an ERP intervention to improve recovery from cardiac surgery. Mean and standard deviation are presented throughout.

		Interv	ention		Comp	arator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	d (95% CI)	Mean change (95% CI)	р
	score (Mean change from baseline)									
Furze 2009 <sup>32</sup>	Cardiac Depression Scale (raw score)	100	81.69		104	93.37				
Furze 2009 <sup>32</sup>	CLASP Mobility subscale (raw score)	100	8.1		104	9.05				
Rosenfeldt 2011 <sup>34</sup>	SF-36 Physical composite score	60	40.6	8.5*1	57	39.4	9.8* <sup>1</sup>	.13 (23 to .49)	1.2 (2.16 to 4.56)	.48
Rosenfeldt 2011 <sup>34</sup>	SF-36 Mental composite score	60	45.6	10.8*1	57	43.1	10.6*1	.23 (13 to .6)	2.5 (-1.42 to 6.42)	.21

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs, imputed where necessary. P-values are from independent samples t-tests. SF-36=Short Form 36; \*Quality Adjusted Life Years: Calculated using EQ-5D questionnaire using area under the curve method; CLASP=Cardiovascular Limitations and Symptoms Profile; \*1SD imputed from SE; n=sample size

		Interv	vention		Com	parator		Intervention	Comparator			
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
Probst 2014 <sup>35</sup> , SW	Total hospital LOS (days)	100	9 (median)	8.0 to 11.0 (IQR)	100	9 (median)	8.0 to 12.0 (IQR)	9.3 (2.3)	9.7 (3)	13 (40 to .15)	33 (-1.08 to .41)	.38
Probst 2014 <sup>35</sup> , SW	LOS on unit (PACU or ICU, h)	100	3.3 (median)	2.7 to 4.0 (IQR)	100	17.9 (median)	10.3 to 24.9 (IQR)	3.3 (1)	17.7 (11)	-1.84 (-2.17 to - 1.51)	-14.4 (-16.5 to -12.2)	<.001
Probst 2014 <sup>35</sup> , SW	LOS on IMC (h)	100	23 (median)	19.9 to 41.8 (IQR)	100	21 (median)	10.5 to 28.8 (IQR)	28.2 (16.5)	20.1 (13.8)	.54 (.25 to .82)	8.1 (3.90 to 12.4)	<.001
Probst 2014 <sup>35</sup> , SW	Overall Intensive Care Treatment (h)	100	30.9 (median)	23.9 to 59.9 (IQR)	100	43.9 (median)	24.9 to 65.4 (IQR)	38.2 (27.1)	44.7 (30.5)	23 (50 to 0.05)	-6.5 (-14.5 to 1.54)	.11
Probst 2014 <sup>35</sup> , SW	Total postoperative complications (n)	100	56		100	86				OR: 0.21 (0.1 to 0.41)		<.001
Probst 2014 <sup>35</sup> , SW	Mortality (n)	100	0		100	3						.08
van der Peijl 2004 <sup>36</sup> , Rehab	Length of stay (days)	134	7 (median)	4 to 15 (range)	112	7 (median)	3 to 18 (range)					
van der Peijl 2004 <sup>36</sup> , Rehab	Activity monitor: locomotion (% of 10h period)	85	3	1.7	85	3	2.3			.0 (3 to .3)	.0 (50 to .50)	1.0
van der Peijl 2004 <sup>36</sup> , Rehab	Activity monitor: time spent standing (% of 10h period)	85	8	5.1	85	8	6.2			.0 (3 to .3)	.0 (-1.42 to 1.42)	1.0
van der Peijl 2004 <sup>36</sup> , Rehab	Activity monitor: time spent sitting (% of 10h period)	85	70	17.2	85	69	22.2			.05 (25 to .35)	1.0 (-5.01 to 7.01)	.74
van der Peijl	Activity monitor:	85	19	18.4	85	20	21.9			05	-1.0	.75

 Table 13. Data for clinical outcomes for studies trialling Specialist Ward or Rehabilitation interventions to improve recovery from cardiac surgery.

 Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.

		Inter	vention		Com	parator		Intervention	Comparator			
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
2004 <sup>36</sup> , Rehab	time spent lying (% of 10h period)									(35 to .25)	(-7.12 to 5.12)	
van der Peijl 2004 <sup>36</sup> , Rehab	Self-care scale	134	38.9	2.5	112	38.9	2.5			0.0 (3 to .3)	.0 (63 to .63)	1.0
van der Peijl 2004 <sup>36</sup> , Rehab	Functional independence measure: Transfers scale	134	20.2	1.2	112	20.2	1.4			0.0 (3 to .3)	.0 (33 to .33)	1.0
van der Peijl 2004 <sup>36</sup> , Rehab	Functional independence measure: Locomotion scale	134	12.2	1.4	112	12.1	1.5			0.1 (2 to .3)	.1 (26 to .46)	.59

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). OR=Odds Ratio; SW=Specialist Ward; Rehab=Rehabilitation; PACU=Post-Anaesthetic Care Unit; ICU=Intensive Care Unit; IMC=Intermediate Care Unit; n=sample size

		Interv	vention		Com	parator		Intervention	Comparator			
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
Chen 2017 <sup>2</sup> (Gastrectomy)	Delirium incidence (%)	43	2.3		43	18.6				OR: 0.1 (0.01 to 0.87)		<.05
Chen 2017 <sup>2</sup> (Gastrectomy)	LOS (days)	43	12 (median)	9.5 to 12.5 (IQR)	43	18 (median)	9.5 to 26.5 (IQR)	12.0 (3.8)	18.0 (13.0)	62 (-1.06 to19)	-6.0 (-10.1 to -1.88)	<.01
Chen 2017 <sup>2</sup> (PD)	Delirium incidence (%)	25	8.0		21	28.6				OR: 0.22 (0.04 to 1.22)		.07
Chen 2017 <sup>2</sup> (PD)	LOS (days)	25	16 (median)	10 to 22 (IQR)	21	25.5 (median)	13 to 38 (IQR)	16.0 (9.4)	25.5 (19.9)	63 (-1.22 to03)	-9.5 (-18.5 to49)	<.05
Jones 2013 <sup>37</sup>	Postop LOS (days)	46	4 (median)	3 to 5 (IQR)	45	7 (median)	6 to 8 (IQR)	4.0 (1.5)	7.0 (1.5)	-1.96 (-2.46 to -1.46)	-3.0 (-3.64 to -2.36)	<.001
Jones 2013 <sup>37</sup>	Readmissions (n)	46	2		45	0						.16
Jones 2013 <sup>37</sup>	Mortality (n)	46	1		45	1						1.0
Jones 2013 <sup>37</sup>	Total liver complications (n)	46	10		45	8				OR: 1.28 (0.46 to 3.62)		.64
Jones 2013 <sup>37</sup>	Patients with liver complications (%)	46	15		45	11				OR: 1.43 (0.41 to 4.91)		.57
Jones 2013 <sup>37</sup>	Number of general complications (n)	46	4		45	20				OR: 0.12 (0.04 to 0.39)		<.001
Jones 2013 <sup>37</sup>	Patients with general complications (n)	46	3		45	12				OR: 0.2 (0.05 to 0.75)		<.05
Kapritsou	LOS (days)	29	5.93	2.49	34	11.91	5.52			-1.36	-5.98	<.001

Table 14. Data for clinical outcomes for each study trialling an ERP intervention to improve recovery from upper abdominal surgery. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.

		Intervention		Com	parator		Intervention	Comparator				
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
2017 <sup>38</sup>										(-1.91 to81)	(-8.20 to -3.76)	
Kapritsou 2017 <sup>38</sup>	Total complications (n)	29	7		34	7				OR: 0.32 (0.11 to 0.94)		<.05
Tanaka 2017 <sup>39</sup>	Allowed day of discharge (days)	73	5 (median)	5 to 7 (IQR)	69	7 (median)	5 to 9.5 (IQR)	5.7 (1.5)	7.2 (3.4)	57 (91 to24)	-1.5 (-2.37 to63)	<.001
Tanaka 2017 <sup>39</sup>	Postop LOS (days)	73	9 (median)	8 to 10 (IQR)	69	10 (median)	9 to 11.5 (IQR)	9.0 (1.5)	10.2 (1.9)	68 (-1.02 to34)	-1.2 (-1.73 to60)	<.001
Tanaka 2017 <sup>39</sup>	Readmissions <30 days (%)	73	1.40		69	1.40				OR: 1 (0.06 to 16.46)		1.0
Tanaka 2017 <sup>39</sup>	Patients with C- D grade C2 complications (%)	73	19.2		69	31.9				OR: 0.51 (0.23 to 1.1)		.08
Tanaka 2017 <sup>39</sup>	Patients with C- D grade C3 complications (%)	73	4.1		69	14.5				OR: 0.25 (0.07 to 0.96)		<.05

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data, imputed where necessary. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). LOS=Length of stay; SD=Standard deviation; CI=Confidence interval; PD=Pancreaticoduodenectomy; OR=Odds Ratio; C-D=Clavien-Dindo; n=sample size

		Interv	vention		Com	parator		Intervention	Comparator			
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	d (95% CI)	Mean change (95% CI)	р
Jones 2013 <sup>37</sup>	Time to being medically fit for discharge (days)	46	3	3-4	45	6	6-7	3.3 (0.8)	6.3 (0.8)	-3.92 (-4.63 to - 3.21)	-3.0 (-3.32 to -2.68)	<.001
Jones 2013 <sup>37</sup>	EQ-5D (Area Under Curve)	46	37.2		45	35.6						
Kapritsou 2017 <sup>38</sup>	Pain (VAS 0-10)	29	6.44	2.76	34	5.86	2.91			.2 (29 to .7)	.58 (86 to 2.02)	.42
Kapritsou 2017 <sup>38</sup>	Behavioral Pain Scale (VAS 0-10)	29	2.09	2.3	34	2.31	2.14			1 (6 to .4)	22 (-1.34 to .90)	.70
Kapritsou 2017 <sup>38</sup>	Sadness (VAS 0-10)	29	4.59	2.27	34	4.39	3.17			.07 (42 to .57)	.2 (-1.21 to 1.61)	.78
Kapritsou 2017 <sup>38</sup>	Stress (VAS 0-10)	29	5.13	2.66	34	4.32	3.41			.26 (24 to .76)	.81 (75 to 2.37)	.30
Kapritsou 2017 <sup>38</sup>	Optimism (VAS 0-10)	29	7.72	2.22	34	7.27	2.68			.18 (31 to .68)	.45 (80 to 1.70)	.48
Kapritsou 2017 <sup>38</sup>	Cortisol (ng/ml)	29	39.64	16.93	34	34.76	16.93			.29 (21 to .79)	4.88 (-3.68 to 13.4)	.26
Kapritsou 2017 <sup>38</sup>	ACTH (pg/m)	29	37.51	86.43	34	36.15	84.18			.02 (48 to .51)	1.36 (-41.7 to 44.4)	.95
Kapritsou 2017 <sup>38</sup>	NPY (ng/ml)	29	0.9	0.24	34	0.75	0.36			.48 (02 to .99)	.15 (01 to .31)	.07
Tanaka 2017 <sup>39</sup>	Passage of first flatus (day)	73	2 (median)	1 to 2 (IQR)	69	2 (median)	1 to 3 (IQR)	1.7 (0.8)	2.0 (1.5)	28 (61 to .05)	33 (73 to .06)	.09
Tanaka 2017 <sup>39</sup>	Passage of first stool (day)	73	3 (median)	2 to 5 (IQR)	69	4 (median)	3 to 5 (IQR)	3.3 (2.3)	4.0 (1.5)	34 (68 to01)	67 (-1.31 to02)	<.05
Tanaka 2017 <sup>39</sup>	Serum concentration of total protein on POD 7 (g/dl)	73	6.2 (median)	5.9 to 6.6 (IQR)	69	6.1 (median)	5.6 to 6.5 (IQR)	6.2 (0.5)	6.1 (0.7)	.27 (06 to .6)	.17 (04 to .37)	.10
Tanaka 2017 <sup>39</sup>	Serum transthyretin	73	16.3 (median)	13.6 to 18.4	69	13.5 (median)	11.1 to 15.9	16.1 (3.6)	13.5 (3.6)	.72 (.38 to 1.06)	2.6 (1.39 to 3.81)	<.001

 Table 15. Data for patient-reported outcomes for each study trialling an ERP intervention to improve recovery from upper abdominal surgery.

 Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.

		Inter	rvention		Com	parator		Intervention	Comparator			
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	d (95% CI)	Mean change (95% CI)	р
	concentration on POD7 (mg/dl)			(IQR)			(IQR)					
Tanaka 2017 <sup>39</sup>	Weight loss, one week post-surgery (ratio of postop to pre-op weight)	73	0.962 (median)	0.955 to 0.976 (IQR)	69	0.957 (median)	0.947 to 0.967 (IQR)	1.0 (0)	1.0 (0)	.45 (.12 to .78)	.007 (.002 to .012)	<.01
Tanaka 2017 <sup>39</sup>	Weight loss, one month post- surgery (ratio of postop to pre-op weight)	73	0.951 (median)	0.928 to 0.971 (IQR)	69	0.937 (median)	0.919 to 0.959 (IQR)	1.0 (0)	0.9 (0)	.38 (.05 to .71)	.011 (.001 to .02)	<.05

Standardised (Cohen's *d*) and non-standardised mean differences with 95% confidence intervals were calculated from means and SDs (imputed where necessary). P-values are from independent samples t-tests. VAS=Visual Analogue Scale; ACTH=Adrenocorticotropic Hormone; NPY=Neuropeptide Y; POD=Postoperative Day; n=sample size

		Interv	vention		Com	parator		Intervention	Comparator			
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean change (95% CI)	р
Dunne 2016 <sup>40</sup>	LOS (days)	19	5 (median)	4 to 6 (IQR)	15	5 (median)	4.5 to 7 (IQR)	5.0 (1.6)	5.5 (2)	28 (96 to .4)	5 (-1.77 to .77)	.43
Dunne 2016 <sup>40</sup>	Duration of stay in critical care (days)	19	1 (median)	1 to 2 (IQR)	15	1.5 (median)	1 to 2 (IQR)	1.3 (0.8)	1.5 (0.8)	21 (89 to .47)	17 (74 to .40)	.55
Dunne 2016 <sup>40</sup>	Patients with complications <30 days (n)	19	8		15	7				OR: 0.83 (0.21 to 3.25)		.79
Dunne 2016 <sup>40</sup>	Readmissions (n)	19	4		15	0						.06
Dunne 2016 <sup>40</sup>	Oxygen uptake at anaerobic threshold (ml per kg per min)	19	11.9	2.2	16	9.4	1.1			1.4 (.65 to 2.15)	2.5 (1.27 to 3.73)	<.001
Dunne 2016 <sup>40</sup>	Oxygen uptake at peak (ml per kg per min)	19	18.9	4.7	16	16.0	3.5			.69 (.01 to 1.38)	2.9 (.00 to 5.80)	<.05
Dunne 2016 <sup>40</sup>	Oxygen pulse at anaerobic threshold (ml/beat)	19	9.3	2.2	16	7.3	1.7			1.01 (.3 to 1.71)	2.0 (.63 to 3.37)	<.01
Dunne 2016 <sup>40</sup>	Oxygen pulse at peak (ml/beat)	19	11.3	2.2	16	9.5	2.0			.85 (.16 to 1.55)	1.8 (.34 to 3.26)	<.05
Dunne 2016 <sup>40</sup>	Peak work rate (W)	19	130.0	34.0	16	117.0	28.0			.41 (26 to 1.09)	13.0 (-8.69 to 34.7)	.23
Dunne 2016 <sup>40</sup>	Heart rate reserve (beats/min)	19	58.0	23.0	16	55.0	22.0			.13 (53 to .8)	3.0 (-12.6 to 18.6)	.70
Dunne 2016 <sup>40</sup>	SF-36: Physical health subscale (raw score)	19	66.0	27.0	16	56.0	15.0			.45 (23 to 1.12)	10.0 (-5.43 to 25.4)	.20
Dunne 2016 <sup>40</sup>	SF-36: Mental health subscale	19	75.0	24.0	16	61.0	25.0			.57 (11 to 1.25)	14.0 (-2.89 to 30.9)	.10

Table 16. Data for all effectiveness outcomes for the one study trialling a Prehabilitation intervention to improve recovery after upper abdominal surgery. Reported values are presented (mean and standard deviation (SD) unless indicated), as well as imputed means and SD where calculated.

		Inter	vention		Com	parator		Intervention	Comparator			
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean change (95% CI)	р
	(raw score)											
Dunne 2016 <sup>40</sup>	SF-36: QoL subscale (raw score)	19	73.0	23.0	16	59.0	21.0			.63 (05 to 1.32)	14.0 (-1.27 to 29.3)	.07
Dunne 2016 <sup>40</sup>	HR: Oxygen uptake at anaerobic threshold (ml per kg per min)	9	11.9	2.2	8	9.4	1.1			1.41 (.33 to 2.49)	2.5 (.66 to 4.34)	<.05
Dunne 2016 <sup>40</sup>	HR: Oxygen uptake at peak (ml per kg per min)	9	18.9	4.7	8	16	3.5			.69 (29 to 1.68)	2.9 (-1.43 to 7.23)	.17
Dunne 2016 <sup>40</sup>	HR: Oxygen pulse at anaerobic threshold (ml/beat)	9	9.3	2.2	8	7.3	1.7			1.01 (01 to 2.03)	2.0 (05 to 4.05)	.06
Dunne 2016 <sup>40</sup>	HR: Oxygen pulse at peak (ml/beat)	9	11.3	2.2	8	9.5	2.0			.85 (15 to 1.85)	1.8 (38 to 3.98)	.10
Dunne 2016 <sup>40</sup>	HR: Peak work rate (W)	9	130.0	34.0	8	117	28.0			.41 (55 to 1.38)	13.0 (-19.5 to 45.5)	.41
Dunne 2016 <sup>40</sup>	HR: Heart rate researve (beats/min)	9	58.0	23.0	8	55.0	22.0			.13 (82 to 1.09)	3.0 (-20.3 to 26.3)	.79
Dunne 2016 <sup>40</sup>	SF-36: Physical health subscale, HR (raw score)	9	66.0	27.0	8	56.0	15.0			.45 (52 to 1.42)	10.00 (-13.0 to 33.0)	.37
Dunne 2016 <sup>40</sup>	SF-36: Mental health subscale, HR (raw score)	9	75.0	24.0	8	61.0	25.0			.57 (4 to 1.55)	14.0 (-11.3 to 39.3)	.26
Dunne 2016 <sup>40</sup>	SF-36: QoL subscale, HR (raw score)	9	73.0	23.0	8	59.0	21.0			.63 (35 to 1.61)	14.0 (-8.88 to 36.9)	.21

		Inter	vention		Com	parator		Intervention	Comparator			
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	Imputed Mean (SD)	Imputed Mean (SD)	<i>d</i> or OR (95% CI)	Mean change (95% CI)	р

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). OR=Odds Ratio; LOS=Length of Stay; HR=High Risk subgroup; SF-36=Short Form 36; W=Watts; SD=Standard Deviation; CI=Confidence Interval; QoL=Quality of Life; n=sample size

Table 17. Data for clinical outcomes for each study trialling an ER	P intervention to impro	rove recovery from pelv	vic surgery. Reported values	s are
presented (mean and standard deviation (SD) unless indicated).				

		Interv	ention		Comp	arator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
Gralla 2007 <sup>41</sup> / Magheli 2011 <sup>42</sup>	Number experiencing complications (n)	25	6		25	14		OR: 0.25 (0.07 to 0.83)		<.05
Gralla 2007 <sup>41</sup> / Magheli 2011 <sup>42</sup>	Postop LOS (days)	25	3.60	1.22	25	6.72	0.94	-2.9 (-3.73 to -2.12)	-3.1 (-3.70 to -2.50)	<.001
Gralla 2007 <sup>41</sup> / Magheli 2011 <sup>42</sup>	Readmissions (n)	25	2		25	1		OR: 2.09 (0.18 to 24.62)		.55
Jensen 2015 <sup>43</sup>	LOS (days)	50	8 (median)	3 to 30 (range)	57	8 (median)	4 to 55 (range)			
Jensen 2015 <sup>43</sup>	Patients with no complications (%)	50	40		57	40		OR: 1 (0.46 to 2.17)		1.0
Jensen 2015 <sup>43</sup>	Patients with 1 complications (%)	50	16		57	30		OR: 0.44 (0.17 to 1.14)		.09
Jensen 2015 <sup>43</sup>	Patients with 2 complications (%)	50	18		57	10		OR: 1.98 (0.64 to 6.1)		.23
Jensen 2015 <sup>43</sup>	Patients with 3 complications (%)	50	12		57	5		OR: 2.59 (0.6 to 11.21)		.19
Jensen 2015 <sup>43</sup>	Patients with 4 complications (%)	50	8		57	7		OR: 1.16 (0.27 to 4.89)		.84
Jensen 2015 <sup>43</sup>	Patients with 5 complications (%)	50	4		57	2		OR: 2.04 (0.2 to 21.03)		.54
Jensen 2015 <sup>43</sup>	Patients with 6 complications (%)	50	2		57	2		OR: 1 (0.07 to 15.07)		1.0
Jensen 2015 <sup>43</sup>	Patients with 7 complications (%)	50	0		57	4				.15
Jensen 2015 <sup>43</sup>	Readmission <30 days (%)	50	30		57	23		OR: 1.43 (0.6 to 3.4)		.41
Jensen 2015 <sup>43</sup>	Mortality <90 days (%)	50	6		57	7		OR: 0.85 (0.18 to 3.99)		.84

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data, imputed where necessary. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). OR=Odds Ratio; LOS=Length of stay; SD=Standard deviation; CI=Confidence interval; Postop=Postoperative; n=sample size

		Interv	ention		Comp	parator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	d (95% CI)	Mean change (95% CI)	р
Gralla 2007 <sup>41</sup> / Magheli 2011 <sup>42</sup>	Time to first deflation or defecation (days)	25	0.76	0.66	25	1.16	0.62	61 (-1.18 to05)	4 (76 to04)	<.05
Gralla 2007 <sup>41</sup> / Magheli 2011 <sup>42</sup>	Satisfaction with length of stay: too short (n)	25	3		24	2				
Gralla 2007 <sup>41</sup> / Magheli 2011 <sup>42</sup>	Satisfaction with length of stay: just right (n)	25	21		24	20				
Gralla 2007 <sup>41</sup> / Magheli 2011 <sup>42</sup>	Satisfaction with length of stay: too long (n)	25	1		24	2				
Gralla 2007 <sup>41</sup> / Magheli 2011 <sup>42</sup>	Satisfaction with general perioperative course - quality as presumed (n)	25	8		24	11				
Gralla 2007 <sup>41</sup> / Magheli 2011 <sup>42</sup>	Satisfaction with general perioperative course - quality better than presumed (n)	25	17		24	13				
Jensen 2015 <sup>43</sup>	Maximum grade Clavien–Dindo score <90 days 0 (n)	50	40		57	40				
Jensen 2015 <sup>43</sup>	Maximum grade Clavien–Dindo score <90 days 1	50	18		57	26				
Jensen 2015 <sup>43</sup>	Maximum grade Clavien–Dindo score <90 days 2 (n)	50	18		57	9				
Jensen 2015 <sup>43</sup>	Maximum grade Clavien–Dindo score	50	16		57	14				

Table 18. Data for patient-reported outcomes for each study trialling an ERP intervention to improve recovery from pelvic surgery. Reported values are presented (mean and standard deviation (SD) unless indicated).

		Interv	vention		Com	parator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	d (95% CI)	Mean change (95% CI)	р
	<90 days 3 (n)									
Jensen 2015 <sup>43</sup>	Maximum grade Clavien–Dindo score <90 days 4 (n)	50	2		57	4				
Jensen 2015 <sup>43</sup>	Maximum grade Clavien–Dindo score <90 days 5 (n)	50	6		57	7				
Jensen 2015 <sup>43</sup>	Time to passage of first flatus (days)	50	1 (median)		57	2 (median)				
Jensen 2015 <sup>43</sup>	Time to passage of first stool (days)	50	4 (median)		57	4 (median)				
Jensen 2015 <sup>43</sup>	Reported pain VAS: 0 (%)	50	72		57	79				
Jensen 2015 <sup>43</sup>	Reported pain VAS; 1- 3 (%)	50	12		57	14				
Jensen 2015 <sup>43</sup>	Reported pain VAS: 4- 5 (%)	50	10		57	7				
Jensen 2015 <sup>43</sup>	Reported pain VAS: 6 or above (%)	50	6		57	0				

Standardised (Cohen's d) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs, imputed where necessary. P-

values are from independent samples t-tests. CI=Confidence Interval; SD=Standard Deviation; VAS=Visual Analogue Scale; n=sample size

		Interve	ention		Compa	arator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
Muehling 2009 <sup>44</sup> , ERP	Postoperative ventilation required (n)	49	3		50	16		OR: 0.11 (0.02 to 0.55)		<.01
Muehling	LOS on ICU (hours)	49	20	14 to 336	50	32	12 to 293			
2009 <sup>44</sup> , ERP		10	(median)	(range)		(median)	(range)			
Muehling	Day of discharge	49	10	6 to 49	50		8 to 45			
2009 <sup>44</sup> , ERP	(postop day)	10	(median)	(range)		(median)	(range)			
Muehling	Duration of I.V. fluid	49	2	1 to 40	50	5	2 to 16			
2009 <sup>44</sup> , ERP	(days)		(median)	(range)		(median)	(range)			
Muehling	Time to full enteral	49	5	4 to 40	50	7	4 to 22			
2009 <sup>44</sup> , ERP	feeding (hours)		(median)	(range)		(median)	(range)			
Muehling	Time to first	49	2	1 to 4	50	2	1 to 5			
2009 <sup>44</sup> , ERP	defecation (hours)		(median)	(range)		(median)	(range)			
Muehling 2009 <sup>44</sup> , ERP	Incidence of complications (%)	49	16		50	36		OR: 0.35 (0.12 to 1.02)		.05
Muehling 2009 <sup>44</sup> , ERP	Deaths (n)	49	0		50	0				
Muehling 2009 <sup>44</sup> , ERP	Readmission <30 days (n)	49	0		50	0				
Muehling 2011 <sup>45</sup> , ERP	Development of SIRS (%)	49	28		50	50		OR: 0.39 (0.17 to 0.9)		<.05
Muehling 2011 <sup>45</sup> , ERP	Occurrence of organ failure (%)	49	16		50	36		OR: 0.34 (0.13 to 0.88)		<.05
Partridge 2017 <sup>46</sup> , PACP	LOS (days)	85	3.32		91	5.53				
Partridge 2017 <sup>46</sup> , PACP	New comorbid diagnoses made at assessment (%)	101	63.40		100	5		OR: 32.91 (12.28 to 88.24)		<.001
Partridge 2017 <sup>46</sup> , PACP	Incidence of postoperative delirium (%)	85	11		91	24		OR: 0.39 (0.17 to 0.9)		<.05

Table 19. Data for all outcomes for studies trialling interventions to improve recovery from vascular surgery. Reported values are presented (mean and standard deviation (SD) unless indicated).

		Interv	ention		Comp	arator				
Study, intervention	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
Partridge 2017 <sup>46</sup> , PACP	Fall (%)	85	2		91	8		OR: 0.23 (0.04 to 1.28)		.07
Partridge 2017 <sup>46</sup> , PACP	Cardiac complications (%)	85	8		91	27		OR: 0.24 (0.09 to 0.58)		<.01
Partridge 2017 <sup>46</sup> , PACP	Pulmonary complications (%)	85	9		91	14		OR: 0.61 (0.23 to 1.57)		.30
Partridge 2017 <sup>46</sup> , PACP	Infective complications (%)	85	16		91	27		OR: 0.51 (0.25 to 1.08)		.08
Partridge 2017 <sup>46</sup> , PACP	Bowel and bladder complications (%)	85	33		91	55		OR: 0.4 (0.22 to 0.74)		<.01
Partridge 2017 <sup>46</sup> , PACP	Postoperative vascular surgery related issues (%)	85	7		91	11		OR: 0.61 (0.21 to 1.76)		.36
Partridge 2017 <sup>46</sup> , PACP	Discharge timed get up and go (seconds)	85	18.9	1.8	91	20.1	11.6	14 (44 to .15)	-1.2 (-3.71 to 1.31)	.35
Partridge 2017 <sup>46</sup> , PACP	Discharge gait speed (m.s <sup>-1</sup> )	85	0.7	0.3	91	0.7	0.2	.0 (3 to .3)	0 (08 to .08)	1.0
Partridge 2017 <sup>46</sup> , PACP	Postoperative blood transfusion (units infused)	85	0.3	0.7	91	1	3.7	26 (56 to .04)	7 (-1.51 to .11)	.09
Partridge 2017 <sup>46</sup> , PACP	Discharge to higher care (%)	85	5		91	13		OR: 0.38 (0.13 to 1.1)		.07
Partridge 2017 <sup>46</sup> , PACP	Readmission to hospital within 30 days (%)	85	18		91	11		OR: 1.95 (0.86 to 4.42)		.10
Partridge 2017 <sup>46</sup> , PACP	Level 2/3 care used immediately after surgery (%)	85	31		91	43		OR: 0.6 (0.32 to 1.11)		.10

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data, imputed where necessary. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). OR=Odds Ratio; ERP=Enhanced Recovery Protocol; PACP=Preoperative Assessment and Care Plan; LOS=Length of Stay; SD=Standard deviation; CI=Confidence interval; SIRS= Systemic Inflammatory Response Syndrome; ICU=Intensive Care Unit; n=sample size

		Interv	ention		Comp	arator				
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	OR (95% CI)	Mean difference (95% CI)	р
Muehling 2008 <sup>47</sup>	Postoperative ventilation required (%)	27	3.7		28	7.1		OR: 0.5 (0.04 to 5.91)		.58
Muehling 2008 <sup>47</sup>	LOS on ICU (hours)	30	1 (median)	1 to 33 (range)	28	1 (median)	1 to 12 (range)			
Muehling 2008 <sup>47</sup>	Day of discharge (postop day)	30	11 (median)	8 to 33 (range)	28	11 (median)	7 to 34 (range)			

Table 20. Data for all outcomes for studies trialling interventions to improve recovery from thoracic surgery. Reported values are presented (mean and standard deviation (SD) unless indicated).

Standardised (Cohen's d) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). OR=Odds Ratio; LOS=Length of Stay; SD=Standard deviation; CI=Confidence interval; ICU=Intensive Care Unit; n=sample size

		Intervention			Comparator					
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
Hempenius 2013 <sup>48</sup>	Incidence of delirium (%)	117	9.4		129	14.3		OR: 0.62 (0.28 to 1.37)		.24
Hempenius 2013 <sup>48</sup>	Severity of delirium (Score on DRS-R-98)	117	9 (median)	3 to 30 (range)	129	15 (median)	5 to 29 (range)			
Hempenius 2013 <sup>48</sup>	Length of hospital stay (days)	117	8 (median)	1 to 135 (range)	129	8 (median)	1 to 44 (range)			
Hempenius 2013 <sup>48</sup>	Patients experiencing >1 complication (%)	117	33.1		129	28.6		OR: 1.24 (0.72 to 2.12)		.45
Hempenius 2013 <sup>48</sup>	Mortality (%)	117	7.9		129	3		OR: 2.77 (0.82 to 9.42)		.09
Hempenius 2013 <sup>48</sup>	Care dependency score (raw score)	112	72.29	8.92	124	73.53	9.08	14 (39 to .12)	-1.24 (-3.55 to 1.07)	.29
Hempenius 2013 <sup>48</sup>	Mini Mental State Examination (raw score)	87	26.68	2.97	92	26.33	3.91	.10 (19 to .39)	.35 (68 to 1.38)	.50
Hempenius 2013 <sup>48</sup>	SF-36 Physical function subscale (% same or better than baseline)	117	22.8		129	23.2				
Hempenius 2013 <sup>48</sup>	SF-36 Social function subscale (% same or better than baseline)	117	44.7		129	45.6				
Hempenius 2013 <sup>48</sup>	SF-36 Role Physical subscale (% same or better than baseline)	117	36		129	30.4				
Hempenius 2013 <sup>48</sup>	SF-36 Role Emotional subscale (% same or better than baseline)	117	48.2		129	59.2				
Hempenius 2013 <sup>48</sup>	SF-36 Mental Health subscale (% same or better than baseline)	117	62.3		129	56.8				
Hempenius	SF-36 Vitality	117	37.7		129	39.2				

Table 21. Data for all outcomes from the study trialling an intervention to improve recovery for patients undergoing various tumour removal surgeries. Reported values are presented (mean and standard deviation (SD) unless indicated).

		Intervention			Comparator					
Study	Outcome (units)	n	Estimate	Variance	n	Estimate	Variance	<i>d</i> or OR (95% CI)	Mean difference (95% CI)	р
201348	subscale (% same or better than baseline)									
Hempenius 2013 <sup>48</sup>	SF-36 Bodily pain subscale (% same or better than baseline)	117	50		129	32.8				
Hempenius 2013 <sup>48</sup>	SF-36 General Health subscale (% same or better than baseline)	117	58.8		129	54.4				
Hempenius 2013 <sup>48</sup>	SF-36 Health Change subscale (% same or better than baseline)	117	64.9		129	72.0				
Hempenius 2013 <sup>48</sup>	Return to pre- operative living situation (%)	117	67.3		129	79.1		OR: 0.54 (0.31 to 0.97)		<.05
Hempenius 2013 <sup>48</sup>	Patients with increased domestic help (%)	117	18.4		129	26.6		OR: 0.62 (0.34 to 1.14)		.12
Hempenius 2013 <sup>48</sup>	Patients with increased care assistance (%)	117	57.5		129	60.0		OR: 0.9 (0.54 to 1.51)		.70
Hempenius 2013 <sup>48</sup>	Patients with increased informal care (%)	111	36.3		124	30.3		OR: 1.31 (0.77 to 2.24)		.32
Hempenius 2016 <sup>49</sup>	Readmissions <3 months (%)	117	22.9		129	18.3		OR: 1.33 (0.71 to 2.47)		.37

Standardised (Cohen's *d*) and non-standardised mean differences with 95% and confidence intervals were calculated from means and SDs for continuous data. Odds ratios and 95% confidence intervals were calculated for dichotomous data. P-values are from independent samples t-tests (for continuous data) or z-scores (for dichotomous data). OR=Odds Ratio; LOS=Length of Stay; SD=Standard deviation; CI=Confidence interval; OR=Odds Ratio; DSRS-98=Delirium Rating Scale - Revised – 98; SF-36=Short Form 36; n=sample size

## References

1. Anderson AD, McNaught CE, MacFie J, Tring I, Barker P, Mitchell CJ. Randomized clinical trial of multimodal optimization and standard perioperative surgical care. *Br J Surg* 2003;**90**:1497-504. <u>https://doi.org/10.1002/bjs.4371</u>

2. Chen CC, Li HC, Liang JT, Lai IR, Purnomo JDT, Yang YT, *et al.* Effect of a Modified Hospital Elder Life Program on Delirium and Length of Hospital Stay in Patients Undergoing Abdominal Surgery: A Cluster Randomized Clinical Trial. *JAMA Surg* 2017;**152**:827-34. <u>https://doi.org/10.1001/jamasurg.2017.1083</u>

3. Forsmo HM, Pfeffer F, Rasdal A, Ostgaard G, Mohn AC, Korner H, *et al.* Compliance with enhanced recovery after surgery criteria and preoperative and postoperative counselling reduces length of hospital stay in colorectal surgery: results of a randomized controlled trial. *Colorectal Dis* 2016;**18**:603-11. <u>https://doi.org/10.1111/codi.13253</u>

4. Garcia-Botello S, Canovas de Lucas R, Tornero C, Escamilla B, Espi-Macias A, Esclapez-Valero P, *et al.* [Implementation of a perioperative multimodal rehabilitation protocol in elective colorectal surgery. A prospective randomised controlled study]. *Cir Esp* 2011;**89**:159-66. <u>https://doi.org/10.1016/j.ciresp.2010.12.004</u>

5. Gatt M, Anderson AD, Reddy BS, Hayward-Sampson P, Tring IC, MacFie J. Randomized clinical trial of multimodal optimization of surgical care in patients undergoing major colonic resection. *Br J Surg* 2005;**92**:1354-62. <u>https://doi.org/10.1002/bjs.5187</u>

6. Khoo CK, Vickery CJ, Forsyth N, Vinall NS, Eyre-Brook IA. A prospective randomized controlled trial of multimodal perioperative management protocol in patients undergoing elective colorectal resection for cancer. *Ann Surg* 2007;**245**:867-72. https://doi.org/10.1097/01.sla.0000259219.08209.36

7. Lee TG, Kang SB, Kim DW, Hong S, Heo SC, Park KJ. Comparison of early mobilization and diet rehabilitation program with conventional care after laparoscopic colon surgery: a prospective randomized controlled trial. *Dis Colon Rectum* 2011;**54**:21-8. <u>https://doi.org/10.1007/DCR.0b013e3181fcdb3e</u>

8. Lidder P, Thomas S, Fleming S, Hosie K, Shaw S, Lewis S. A randomized placebo controlled trial of preoperative carbohydrate drinks and early postoperative nutritional supplement drinks in colorectal surgery. *Colorectal Dis* 2013;**15**:737-45. <u>https://doi.org/10.1111/codi.12130</u>

9. Maggiori L, Rullier E, Lefevre JH, Regimbeau JM, Berdah S, Karoui M, *et al.* Does a Combination of Laparoscopic Approach and Full Fast Track Multimodal Management Decrease Postoperative Morbidity?: A Multicenter Randomized Controlled Trial. *Ann Surg* 2017;**266**:729-37. <u>https://doi.org/10.1097/SLA.0000000002394</u>

10. Mari GM, Costanzi A, Maggioni D, Origi M, Ferrari GC, De Martini P, *et al.* Fasttrack versus standard care in laparoscopic high anterior resection: a prospective randomizedcontrolled trial. *Surg Laparosc Endosc Percutan Tech* 2014;**24**:118-21. <u>https://doi.org/10.1097/SLE.0b013e3182a50e3a</u>

11. Mari G, Costanzi A, Crippa J, Falbo R, Miranda A, Rossi M, *et al.* Surgical Stress Reduction in Elderly Patients Undergoing Elective Colorectal Laparoscopic Surgery within an ERAS Protocol. *Chirurgia (Bucur)* 2016;**111**:476-80. https://doi.org/10.21614/chirurgia.111.6.476 12. Muller S, Zalunardo MP, Hubner M, Clavien PA, Demartines N. A fast-track program reduces complications and length of hospital stay after open colonic surgery. *Gastroenterology* 2009;**136**:842-7. <u>https://doi.org/10.1053/j.gastro.2008.10.030</u>

13. Pappalardo G, Coiro S, De Lucia F, Giannella A, Ruffolo F, Frattaroli FM. Open sphincter-preserving surgery of extraperitoneal rectal cancer without primary stoma and Fast Track Protocol. *G Chir* 2016;**37**:257-61. <u>https://doi.org/10.11138/gchir/2016.37.6.257</u>

14. Vlug MS, Wind J, Hollmann MW, Ubbink DT, Cense HA, Engel AF, *et al.* Laparoscopy in combination with fast track multimodal management is the best perioperative strategy in patients undergoing colonic surgery: a randomized clinical trial (LAFA-study). *Ann Surg* 2011;**254**:868-75. <u>https://doi.org/10.1097/SLA.0b013e31821fd1ce</u>

15. Carli F, Charlebois P, Stein B, Feldman L, Zavorsky G, Kim DJ, *et al.* Randomized clinical trial of prehabilitation in colorectal surgery. *Br J Surg* 2010;**97**:1187-97. <u>https://doi.org/10.1002/bjs.7102</u>

16. Dronkers JJ, Lamberts H, Reutelingsperger IM, Naber RH, Dronkers-Landman CM, Veldman A, *et al.* Preoperative therapeutic programme for elderly patients scheduled for elective abdominal oncological surgery: a randomized controlled pilot study. *Clin Rehabil* 2010;**24**:614-22. <u>https://doi.org/10.1177/0269215509358941</u>

17. Gillis C, Li C, Lee L, Awasthi R, Augustin B, Gamsa A, *et al.* Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer. *Anesthesiology* 2014;**121**:937-47. <u>https://doi.org/10.1097/aln.00000000000393</u>

18. Borgwardt L, Zerahn B, Bliddal H, Christiansen C, Sylvest J, Borgwardt A. Similar clinical outcome after unicompartmental knee arthroplasty using a conventional or accelerated care program: a randomized, controlled study of 40 patients. *Acta Orthop* 2009;**80**:334-7. <u>https://doi.org/10.3109/17453670903035559</u>

19. Larsen K, Sorensen OG, Hansen TB, Thomsen PB, Soballe K. Accelerated perioperative care and rehabilitation intervention for hip and knee replacement is effective: a randomized clinical trial involving 87 patients with 3 months of follow-up. *Acta Orthop* 2008;**79**:149-59. <u>https://doi.org/10.1080/17453670710014923</u>

20. Pour AE, Parvizi J, Sharkey PF, Hozack WJ, Rothman RH. Minimally invasive hip arthroplasty: what role does patient preconditioning play? *J Bone Joint Surg Am* 2007;**89**:1920-7. <u>https://doi.org/10.2106/jbjs.f.01153</u>

21. Reilly KA, Beard DJ, Barker KL, Dodd CA, Price AJ, Murray DW. Efficacy of an accelerated recovery protocol for Oxford unicompartmental knee arthroplasty--a randomised controlled trial. *Knee* 2005;**12**:351-7. <u>https://doi.org/10.1016/j.knee.2005.01.002</u>

22. Siggeirsdottir K, Olafsson O, Jonsson H, Iwarsson S, Gudnason V, Jonsson BY. Short hospital stay augmented with education and home-based rehabilitation improves function and quality of life after hip replacement: randomized study of 50 patients with 6 months of follow-up. *Acta Orthop* 2005;**76**:555-62. <u>https://doi.org/10.1080/17453670510041565</u>

23. Crowe J, Henderson J. Pre-arthroplasty rehabilitation is effective in reducing hospital stay. *Can J Occup Ther* 2003;**70**:88-96. <u>https://doi.org/10.1177/000841740307000204</u>

24. Hoogeboom TJ, Dronkers JJ, van den Ende CH, Oosting E, van Meeteren NL. Preoperative therapeutic exercise in frail elderly scheduled for total hip replacement: a randomized pilot trial. *Clin Rehabil* 2010;**24**:901-10. https://doi.org/10.1177/0269215510371427 25. Huang SW, Chen PH, Chou YH. Effects of a preoperative simplified home rehabilitation education program on length of stay of total knee arthroplasty patients. *Orthop Traumatol Surg Res* 2012;**98**:259-64. <u>https://doi.org/10.1016/j.otsr.2011.12.004</u>

26. McGregor AH, Rylands H, Owen A, Dore CJ, Hughes SP. Does preoperative hip rehabilitation advice improve recovery and patient satisfaction? *J Arthroplasty* 2004;**19**:464-8.

27. Williamson L, Wyatt MR, Yein K, Melton JT. Severe knee osteoarthritis: a randomized controlled trial of acupuncture, physiotherapy (supervised exercise) and standard management for patients awaiting knee replacement. *Rheumatology (Oxford)* 2007;**46**:1445-9. <u>https://doi.org/10.1093/rheumatology/kem119</u>

28. den Hertog A, Gliesche K, Timm J, Muhlbauer B, Zebrowski S. Pathway-controlled fast-track rehabilitation after total knee arthroplasty: a randomized prospective clinical study evaluating the recovery pattern, drug consumption, and length of stay. *Arch Orthop Trauma Surg* 2012;**132**:1153-63. <u>https://doi.org/10.1007/s00402-012-1528-1</u>

29. Vesterby MS, Pedersen PU, Laursen M, Mikkelsen S, Larsen J, Soballe K, *et al.* Telemedicine support shortens length of stay after fast-track hip replacement. *Acta Orthop* 2017;**88**:41-7. <u>https://doi.org/10.1080/17453674.2016.1256939</u>

30. Huddleston JM, Long KH, Naessens JM, Vanness D, Larson D, Trousdale R, *et al.* Medical and surgical comanagement after elective hip and knee arthroplasty: a randomized, controlled trial. *Ann Intern Med* 2004;**141**:28-38.

31. Arthur HM, Daniels C, McKelvie R, Hirsh J, Rush B. Effect of a preoperative intervention on preoperative and postoperative outcomes in low-risk patients awaiting elective coronary artery bypass graft surgery. A randomized, controlled trial. *Ann Intern Med* 2000;**133**:253-62.

32. Furze G, Dumville JC, Miles JN, Irvine K, Thompson DR, Lewin RJ. "Prehabilitation" prior to CABG surgery improves physical functioning and depression. *Int J Cardiol* 2009;**132**:51-8. <u>https://doi.org/10.1016/j.ijcard.2008.06.001</u>

33. Goodman H, Parsons A, Davison J, Preedy M, Peters E, Shuldham C, *et al.* A randomised controlled trial to evaluate a nurse-led programme of support and lifestyle management for patients awaiting cardiac surgery 'Fit for surgery: Fit for life' study. *Eur J Cardiovasc Nurs* 2008;**7**:189-95. <u>https://doi.org/10.1016/j.ejcnurse.2007.11.001</u>

34. Rosenfeldt F, Braun L, Spitzer O, Bradley S, Shepherd J, Bailey M, *et al.* Physical conditioning and mental stress reduction--a randomised trial in patients undergoing cardiac surgery. *BMC Complement Altern Med* 2011;**11**:20. <u>https://doi.org/10.1186/1472-6882-11-20</u>

35. Probst S, Cech C, Haentschel D, Scholz M, Ender J. A specialized post anaesthetic care unit improves fast-track management in cardiac surgery: a prospective randomized trial. *Crit Care* 2014;**18**:468. <u>https://doi.org/10.1186/s13054-014-0468-2</u>

36. van der Peijl ID, Vliet Vlieland TP, Versteegh MI, Lok JJ, Munneke M, Dion RA. Exercise therapy after coronary artery bypass graft surgery: a randomized comparison of a high and low frequency exercise therapy program. *Ann Thorac Surg* 2004;**77**:1535-41. https://doi.org/10.1016/j.athoracsur.2003.10.091

37. Jones C, Kelliher L, Dickinson M, Riga A, Worthington T, Scott MJ, *et al.* Randomized clinical trial on enhanced recovery versus standard care following open liver resection. *Br J Surg* 2013;**100**:1015-24. <u>https://doi.org/10.1002/bjs.9165</u> 38. Kapritsou M, Papathanassoglou ED, Bozas E, Korkolis DP, Konstantinou EA, Kaklamanos I, *et al.* Comparative Evaluation of Pain, Stress, Neuropeptide Y, ACTH, and Cortisol Levels Between a Conventional Postoperative Care Protocol and a Fast-Track Recovery Program in Patients Undergoing Major Abdominal Surgery. *Biol Res Nurs* 2017;**19**:180-9. <u>https://doi.org/10.1177/1099800416682617</u>

39. Tanaka R, Lee SW, Kawai M, Tashiro K, Kawashima S, Kagota S, *et al.* Protocol for enhanced recovery after surgery improves short-term outcomes for patients with gastric cancer: a randomized clinical trial. *Gastric Cancer* 2017;**20**:861-71. https://doi.org/10.1007/s10120-016-0686-1

40. Dunne DFJ, Jack S, Jones RP, Jones L, Lythgoe DT, Malik HZ, *et al.* Randomized clinical trial of prehabilitation before planned liver resection. *Br J Surg* 2016;**103**:504-12. <u>https://doi.org/10.1002/bjs.10096</u>

41. Gralla O, Haas F, Knoll N, Hadzidiakos D, Tullmann M, Romer A, *et al.* Fast-track surgery in laparoscopic radical prostatectomy: basic principles. *World J Urol* 2007;**25**:185-91. <u>https://doi.org/10.1007/s00345-006-0139-2</u>

42. Magheli A, Knoll N, Lein M, Hinz S, Kempkensteffen C, Gralla O. Impact of fasttrack postoperative care on intestinal function, pain, and length of hospital stay after laparoscopic radical prostatectomy. *J Endourol* 2011;**25**:1143-7. <u>https://doi.org/10.1089/end.2011.0020</u>

43. Jensen BT, Petersen AK, Jensen JB, Laustsen S, Borre M. Efficacy of a multiprofessional rehabilitation programme in radical cystectomy pathways: a prospective randomized controlled trial. *Scand J Urol* 2015;**49**:133-41. <u>https://doi.org/10.3109/21681805.2014.967810</u>

44. Muehling B, Schelzig H, Steffen P, Meierhenrich R, Sunder-Plassmann L, Orend KH. A prospective randomized trial comparing traditional and fast-track patient care in elective open infrarenal aneurysm repair. *World J Surg* 2009;**33**:577-85. <u>https://doi.org/10.1007/s00268-008-9892-2</u>

45. Muehling BM, Ortlieb L, Oberhuber A, Orend KH. Fast track management reduces the systemic inflammatory response and organ failure following elective infrarenal aortic aneurysm repair. *Interact Cardiovasc Thorac Surg* 2011;**12**:784-8. <u>https://doi.org/10.1510/icvts.2010.262337</u>

46. Partridge JS, Harari D, Martin FC, Peacock JL, Bell R, Mohammed A, *et al.* Randomized clinical trial of comprehensive geriatric assessment and optimization in vascular surgery. *Br J Surg* 2017;**104**:679-87. <u>https://doi.org/10.1002/bjs.10459</u>

47. Muehling BM, Halter GL, Schelzig H, Meierhenrich R, Steffen P, Sunder-Plassmann L, *et al.* Reduction of postoperative pulmonary complications after lung surgery using a fast track clinical pathway. *Eur J Cardiothorac Surg* 2008;**34**:174-80. https://doi.org/10.1016/j.ejcts.2008.04.009

48. Hempenius L, Slaets JP, van Asselt D, de Bock GH, Wiggers T, van Leeuwen BL. Outcomes of a Geriatric Liaison Intervention to Prevent the Development of Postoperative Delirium in Frail Elderly Cancer Patients: Report on a Multicentre, Randomized, Controlled Trial. *PLoS ONE* 2013;**8**:e64834.

49. Hempenius L, Slaets J, Asselt D, Bock T, Wiggers T, Leeuwen B. Long Term Outcomes of a Geriatric Liaison Intervention in Frail Elderly Cancer Patients. *PloS ONE* 2016;**11**:e0143364. <u>https://doi.org/10.1371/journal.pone.0143364</u>